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CHAPTER 1 INTRODUCTION 
  
 
 
1.1 Motivation 
 
Campylobacter jejuni is one of the leading causes of human bacterial illness in the world.  
The majority of cases of campylobacteriosis are associated with the consumption of raw or 
undercooked poultry meat or cross-contamination with other food products.  Fewer than 500 
cells are estimated to cause illness symptoms of diarrhea, abdominal pain, and in rare cases 
Guillain-Barré syndrome (Young et al., 2007).  Strategies to reduce the presence of 
Campylobacter in the poultry supply are underdeveloped.     
Maternal antibodies protect broiler chickens from colonization by C. jejuni up until three 
weeks of age.  Subsequently, C. jejuni colonizes the cecum of broiler chickens at 10
8
 colony-
forming units per gram of cecal contents.  Coprophagy, consumption of feces, spreads C. jejuni 
throughout the broiler chicken flock.  C. jejuni outer membrane proteins are recognized by the 
host immune system in response to colonization.  Particularly important is the surface-displayed 
protein, Fibronectin-like protein A (FlpA), responsible for C. jejuni attachment to host epithelial 
cells (Konkel et al., 2010).  Vaccine strategies may exploit expression of FlpA for eliciting a 
broiler chicken immune response within a critical window of time.  
Lactobacillus is considered Generally Recognized as Safe (GRAS) by the U.S. Food and 
Drug Administration, with an extensive history in human food products.  Poultry producers have 
previously adopted probiotic feeding and have benefited from improved broiler weight gain and 
control of intestinal human pathogens (Kalavathy et al., 2003, Schneitz., 2005).  Probiotics 
function under several proposed mechanisms, with numerous studies conducted to evaluate the 
efficacy of lactobacilli (see Chapter 2.2 Review of Literature for more information on 
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probiotics).  Select lactobacilli strains produce a proteinaceous, paracrystalline surface-layer (S-
layer) structure on their exterior, with potential significance in attachment to host epithelial cells. 
In addition to their role as probiotics, recombinant lactobacilli offer a viable vaccine 
candidate and a novel approach for expression of select proteins to elicit host immune responses 
(Wells, 2011).  At an early age, dosage of broiler chickens with recombinant lactobacilli elicits a 
host immune response prior to exposure to C. jejuni.  Limited research evaluates the efficacy of 
these strains when orally administered to broiler chickens. 
The literature indicates current intervention techniques incompletely eliminate pathogen 
colonization, though a minor reduction may significantly reduce the impact on human illness.  
Future analysis must focus on the efficacy of commercialized lactobacilli strains, intended for 
administration in the oral tract of broiler chickens.  Treatment at the farm reduces the 
introduction of Campylobacter into the retail market and decreases the incidence of 
campylobacteriosis.  
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1.2 Objectives 
 
The overall objectives of this research were to 1) colonize broiler chickens with 
Campylobacter jejuni; 2) construct recombinant Lactobacillus for oral delivery of vaccines 
against C. jejuni; and 3) evaluate the immunogenicity of the recombinant Lactobacillus strains in 
broiler chickens.  To meet these objectives, Lactobacillus strains were engineered to express C. 
jejuni FlpA Domain II under a promoter fused to a secretion signal with or without an anchoring 
signal from the mucus-binding protein of L. acidophilus NCFM.  Additional work must be 
conducted to evaluate the exterior protein expression and in vivo antigen-immune response 
within broiler chickens.  If successful, the recombinant Lactobacillus strain could be an attractive 
candidate as a food-grade live vaccine against Campylobacter colonization.  In addition, a non-
genetically modified delivery approach was proposed utilizing three cell wall binding domains. 
 
1.3 References 
Kalavathy R., Abdullah N., Jalaludin S., Ho Y. W. (2003). Effects of Lactobacillus cultures 
on growth performance, abdominal fat deposition, serum lipids and weight of organs of broiler 
chickens. Br Poult Sci 44, 139-144. 
Konkel M. E., Larson C. L., Flanagan R. C. (2010). Campylobacter jejuni FlpA binds 
fibronectin and is required for maximal host cell adherence. J Bacteriol 192, 68-76. 
Schneitz C. (2005). Competitive exclusion in poultry - 30 years of research. Food Cont , 657-
667. 
Wells J. (2011). Mucosal vaccination and therapy with genetically modified Lactic Acid 
Bacteria. Annu Rev Food Sci Technol 2, 423-445. 
Young K. T., Davis L. M., Dirita V. J. (2007). Campylobacter jejuni: Molecular biology and 
pathogenesis. Nat Rev Microbiol 5, 665-679. 
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CHAPTER 2 REVIEW OF LITERATURE 
 
 
 
As a leading foodborne pathogen in the United States, Campylobacter jejuni has a high 
incidence in retail poultry meat products, with 845,000 illnesses estimated annually (Batz et al., 
2011).  Several studies have found that greater than 60% of raw retail chicken tested positively 
for this organism (Nannapaneni et al., 2005, Wong et al., 2007, Zhao et al., 2001).  In the United 
States, reports estimate the annual financial burden of Campylobacter-poultry associated health 
care costs at $1.2 billion.  Additionally, it is estimated that 9,000 Quality Adjusted Life Years are 
lost annually (Batz et al., 2011).  Therefore, reduction of C. jejuni presence in chicken products 
is a public health concern. 
This review will first provide an introduction to Campylobacter spp., particularly C. 
jejuni and Lactobacillus spp.  The review will then focus upon understanding the role of 
lactobacilli as probiotics and vaccines, particularly the expression and localization of proteins.  It 
will also address how the poultry industry could administer recombinant lactobacilli as a 
potential solution for the reduction of C. jejuni colonization in broiler chickens.  It will conclude 
with discussion about the selection of the optimal lactobacilli strain, promoter, protein 
presentation, adjuvant, and study parameters to increase the probability of experimental in vivo 
success. 
 
2.1 Campylobacter  
 
Campylobacter spp. are characterized as gram-negative, curved-shaped, microaerophilic 
bacteria with flagellar motility.  Of the various species, Campylobacter coli, Campylobacter 
fetus, and C. jejuni cause foodborne diseases in humans; with the latter being more heavily 
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studied.  Parkhill, et al. (2000) published the C. jejuni NCTC 11168 genome, increasing 
knowledge of the relatively small genome (1.6 million bp) and demonstrated the prevalence of 
hypervariable sequences.  Subsequent research has elucidated a great deal of diversity and 
variation amongst strains, which may be critical for survival. 
 
Environmental Reservoirs of Campylobacter 
 
Interestingly, C. jejuni does not survive outside the host for an extended period and is 
susceptible to low pH environments and is sensitive to high oxygen-containing environments.  
Common environmental reservoirs of Campylobacter spp. are agricultural commodities (poultry, 
cattle, sheep, and pigs), wild animals (birds, rabbits, and rodents), and domestic animals.  
Additionally, Campylobacter spp. are often isolated from environmental samples including 
sewage, surface and coastal waters (Humphrey et al., 2007, Jones, 2001).   
Campylobacter is especially pervasive through poultry farms and is the target agricultural 
commodity for intervention.  Typically, a broiler chicken becomes colonized with 
Campylobacter in the ceca. Campylobacter spp. are shed through the excreta.  Widespread 
colonization occurs within a few days due to the practice of coprophagy.  Broiler flocks are often 
colonized with C. jejuni by three weeks of age, perhaps due to age-related mechanisms including 
the declining presence of maternal antibodies (Sahin et al., 2003, Wigley, 2013).  Within the GIT 
of chickens, colonization is highest in the mucosal layer of cecal crypts (between 10
6
 and 10
8
 
colony-forming unit (CFU)/g cecal contents) (Allen et al., 2008, Beery et al., 1988, Hermans et 
al., 2012, Meade et al., 2009).  During defeathering and evisceration of these contaminated 
carcasses, processing steps spread Campylobacter strains between flocks and further exacerbate 
the incidence of C. jejuni in retail chicken meat (Hermans et al., 2011b). 
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Campylobacteriosis Pathology 
It is estimated that as few as 500-800 Campylobacter cells may result in infection and 
development of campylobacteriosis in humans (Young et al., 2007).  Patients of all ages 
experience a range of symptoms from asymptomatic to severe illness.  Symptoms of the self-
limiting gastroenteritis may include fever, abdominal cramping, diarrhea, and malaise, which 
may last between several days to one week (Godschalk et al., 2004, Jay et al., 2005, Nyati & 
Nyati., 2013).  A strong correlation exists between individuals with prior episodes of C. jejuni 
infections and Guillain-Barré syndrome (GBS); these mechanisms have been extensively 
reviewed (Hughes & Cornblath, 2005, Kuwabara & Yuki, 2013, Nachamkin et al., 1998, Yuki & 
Odaka, 2005).  In the rare case of GBS, the lipooligosaccharide present on the surface of C. 
jejuni molecularly mimics the human neuronal gangliosides (Young et al., 2007).  As host 
elicited antibodies react with peripheral nerve targets, this auto-immune response attacks the 
myelin sheath of the central nervous system and may result in ascending paralysis.  While most 
patients with GBS are able to recover with mild side effects, total paralysis and death may result 
for patients that do not receive sufficient treatment.   
 
Mechanisms of Campylobacter Colonization, Attachment, and Invasion 
The mechanisms responsible for campylobacteriosis in humans are not well understood.  
A great deal can be learned from C. jejuni colonization of broiler chickens.  In the 
gastrointestinal tract (GIT), Campylobacter survival, colonization, and virulence is impacted by 
both host and Campylobacter produced factors.  Host defenses include frequent turnover of the 
mucosal layer and epithelial cells, an innate immune system, and a commensal microbial 
community (Ivanov & Honda, 2012, Kim et al., 2010).  Conversely, chemotaxis, flagellar 
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motility, exterior protein display, and iron regulation promote Campylobacter passage through 
the GI lumen and colonization of the basolateral surface of the host epithelial cell (Hermans et 
al., 2011a, Montville et al., 2012, Young et al., 2007).  Motility is critical for C. jejuni 
colonization, as non-motile strains colonize broiler chickens at considerably lower levels and 
have greater difficulty in reaching the deep cecal crypts and resisting host defense mechanisms.   
In addition, great variation of the lipooligosaccharide structure is present amongst 
Campylobacter spp. (Karlyshev et al., 2005).  As this organism is found predominantly in the 
GIT, this structure may be integral for colonization of a wide assortment of hosts and intestinal 
niches.  Surface-displayed proteins interact with host binding sites and influence colonization 
(Flanagan et al., 2009).  Though lacking visible surface pili, C. jejuni attach to host epithelial 
cells through binding of the Campylobacter adhesion to fibronectin (CadF) outer membrane 
protein and the fibronectin-like protein A (FlpA) (Konkel et al., 1997, Konkel et al., 2010).  
These adhesins are required for maximal C. jejuni binding and invasion, though additional 
adhesins are also present that promote attachment.  Secretion of the virulence proteins, termed 
Campylobacter invasion antigens (CiA), from the bacterium’s flagellar Type III Secretion 
System (T3SS) are required for maximal cell invasion (Christensen et al., 2009, Konkel et al., 
1999, Konkel et al., 2004, Malik-Kale et al., 2008).  The promotion of the C. jejuni invasion has 
been attributed to the ability of the CiA proteins to modify the host cell regulation pathways.  
Further research on C. jejuni surface proteins and colonization of host epithelial cells will 
provide clarification of the mechanisms for pathogenicity 
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Intervention Strategies 
To reduce the incidence of campylobacteriosis, present strategies focus on the reduction 
of Campylobacter spp. at the farm (Hermans et al., 2011b).  Previously, antibiotics were 
supplemented in chicken feed to prevent acquisition of harmful bacterial species including C. 
jejuni.  However, antibiotics negatively impact the composition and function of the microbiome 
as well as physiology of the chicken, resulting in antibiotic-resistant pathogens (Luangtongkum 
et al., 2009, Miles et al., 2006, Smith et al., 1999).  Alternative research strategies have included 
development of a live-attenuated Salmonella vaccine which expresses Campylobacter antigens, a 
formalin inactivated C. jejuni whole cell vaccine, and a recombinant Escherichia coli clone 
which expresses fusion proteins from the C. jejuni flagellin gene (Buckley et al., 2010, Rice et 
al., 1997, Widders et al., 1998).  Annamalai, et al. (2013) demonstrated that vaccinated groups 
with encapsulated C. jejuni outer membrane proteins (OMP) or solely OMP vaccinated 
subcutaneously induce a protective antibody response and prevent C. jejuni colonization in the 
chicken.  However, the subcutaneous vaccination method is not feasible for large-scale 
application in broiler farms.  Presently, there are no commercially available vaccines which fully 
eradicate C. jejuni colonization in poultry.  A key emphasis of treatment methods should be 
placed upon reduction of colonization within the ceca and conservation amongst C. jejuni 
isolates.   
Our limited understanding of the mechanisms responsible for C. jejuni colonization and 
invasion make it difficult to develop approaches to prevent campylobacteriosis.  Both researchers 
and feed companies seek a strategy to control C. jejuni colonization of broiler chickens, to 
promote the GI health of the animal while reducing or eliminating the presence of C. jejuni.  In 
poultry, the GIT serves as the only site of amplification for these pathogens through the food 
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chain (Wagenaar et al., 2006).  Lactobacillus has been successfully isolated and characterized 
from the intestinal contents of broiler chickens (Ham et al., 2011, Ojala et al., 2010).  At the 
farm, probiotics given to broiler chickens offer the benefit of reducing human exposure to these 
pathogens.  Oral gavage of lactobacilli-based treatments prior to inoculation of C. jejuni resulted 
in decreased C. jejuni colonization in cecum samples (Neal-McKinney et al., 2012).  Under this 
probiotic method, the researchers orally dosed broiler chicks with 10
7
 CFU/mL Lactobacillus 
spp. and followed four days later with a booster shot.  At fourteen days post hatch, the broiler 
chicks were then orally inoculated with C. jejuni at 10
9
 CFU/mL.  Several days after C. jejuni 
inoculation and subsequent colonization, the broiler chicks were euthanized.  Upon analyzing the 
culture-based methods, the Lactobacillus spp. differed in their ability to reduce C. jejuni 
colonization. While L. crispatus was found to effectively reduce C. jejuni, L. gallinarum did not 
reduce colonization in any of the inoculated chickens.  Further research must be conducted to 
evaluate these strain variations.   
Attenuated Salmonella vectors expressing linear peptides of Campylobacter have 
decreased the C. jejuni colonization of challenged chickens to undetectable levels.  Vaccination 
with Cj0113 (Omp18) in the Salmonella vector resulted in a strong humoral response with sIgA 
concentrations measured from the ileum mucosa (Layton et al., 2011).  Alternative research 
studies may consider C. jejuni colonization-associated proteins expressed on the surface of 
GRAS organisms.  This two-part approach exploits probiotic and vaccine mechanisms for 
reduction of C. jejuni colonization in the gastrointestinal tract of broiler chickens.   
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2.2 Lactobacillus 
 
Lactic Acid Bacteria (LAB) are a taxonomically-related group of microorganisms, 
characterized as Gram-positive, non-pathogenic microorganisms that produce lactic acid as the 
primary end-product of carbohydrate metabolism.  The genus Lactobacillus, a member of the 
LAB, contains non-spore forming, anaerobic or microaerophilic, fermentative, and catalase-
negative microorganisms with complex nutritional requirements (Jay et al., 2005).   
 
 
Environmental Reservoirs for Lactobacillus spp. 
 
These organisms have been isolated from numerous environments, including fermented 
food, plants, fecal material, sewage, silage, as well as the healthy GIT of humans and animals 
(Magnusson et al., 2003, Siezen et al., 2010).  Lactobacillus spp. have been found in fermented 
foods including kimchi, cheese, sausage, sourdough, as well as pickles.  Plant isolates have been 
found in lilac flowers, grass, dandelion flowers, rowan leaves, and coltsfoot flower.  
Lactobacillus spp. are considered commensal microorganisms that colonize the GIT of humans 
and animals. 
 
 
Regulatory Designation for Lactobacillus spp. 
 
The Food and Drug Administration (FDA) recognizes the historical use of Lactobacillus 
spp. in the food industry and classifies the food additive as Generally Recognized As Safe 
(GRAS).  This genus has been widely used as probiotics and vaccines, owing to the reported 
beneficial health effects (Avall-Jaaskelainen & Palva, 2005, Bernardeau et al., 2008, Borchers et 
al., 2009).  Lactobacillus species also have promise for use as therapeutics and prophylactics. 
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While the poultry industry has accepted the oral administration of Lactobacillus spp., 
federal regulations for probiotics in humans and animal feed remain to be clearly defined 
(Anadon et al., 2006, Degnan, 2008).  In the United States, the Food and Drug Administration 
(FDA) requires GRAS status for microorganisms intended for human consumption.  In Europe, 
the European Food Safety Authority (EFSA) serves as the European Union (EU) risk assessment 
body for food and feed safety.  The Panel on Additives and Products or Substances used in 
Animal Feed (FEEDAP) provides independent scientific advice regarding the safety and/or 
efficacy of additives and products or substances used in animal feed.  EFSA proposed a list of 
microorganisms for QPS status, based upon historical safety (EFSA, 2007).  The Qualified 
Presumption of Safety (QPS) system evaluates the safety of microorganisms in the food chain 
through an ongoing dialog, as the literature evolves. 
 
 
Lactobacillus as Probiotics 
Upon adhesion to the mucosal layer, probiotic functionality involves several proposed 
mechanisms.  These include, but are not limited to, coaggregation with pathogens, competitive 
exclusion, decreased pH of the intestinal lumen, secretion of specific compounds such as 
bacteriocins, improved mucosal barrier function, and modulation of the immune response (Bron 
et al., 2011, Fooks & Gibson, 2002, Klaenhammer, 1995).  Inhibition of pathogenic bacteria 
adhesion to epithelial cell surface receptors occurs via numerous mechanisms, including 
competitive exclusion (lactobacilli bind before pathogens) and competition (lactobacilli and 
pathogens presented simultaneously).  Even transient colonization of the GIT allows the 
probiotics to provide these beneficial effects to the host. 
12 
 
Lactobacillus strains stimulate or modulate the immune system by increasing defenses 
against infection, increasing IgA production, regulating of T-helper 1 cells, altering cytokine 
profiles, and inducing maturation of dendritic cells (Christensen et al., 2002, Duong, 2011, 
Havenith et al., 2002).  In addition, antimicrobial activities are associated with the S-layer 
proteins of several Lactobacillus species, including Lactobacillus helveticus, Lactobacillus 
crispatus, and Lactobacillus kefir (Jakava-Viljanen & Palva, 2007, Wang et al., 2008).  These 
species have shown inhibition of pathogen colonization, such as Salmonella enterica serovar 
Enteritidis (Golowczyc et al., 2007, Pascual et al., 1999) and Salmonella enterica serovar 
Typhimurium (Chen et al., 2012).  Though, this requires further insight into the fundamental 
antimicrobial mechanisms.   
 
Lactobacillus’ Vaccine Potential 
While previous research has focused on administration of live vaccines and live 
attenuated strains for bacterial delivery of pathogenic bacteria, including Salmonella, Bordetella, 
and Listeria (Detmer & Glenting, 2006), the pathogenicity of these vaccines is of great concern.  
Researchers are cognizant of the potential reversion of attenuated pathogenic strains that may 
colonize and replicate within the host’s GIT.  The use of non-pathogenic microorganisms such as 
recombinant lactobacilli may overcome these concerns and offer a strategy of a sound delivery 
vector.  At this time, lactobacilli have been utilized for vaccine development utilizing genes from 
Streptococcus pneumoniae, Helicobacter pylori, Enterotoxigenic E. coli, Listeria 
monocytogenes, as well as Human immunodeficiency virus (HIV) (Tarahomjoo, 2012).  The 
ability of lactobacilli to survive the harsh environmental conditions of the GIT allows the 
13 
 
organism to reach the intended luminal location intact.  Additionally, the recombinant 
microorganism may be shed with minimal concern of further propagation in the environment.     
 
 
2.3 Lactobacillus Characteristics 
 
Surface Layer 
 
The majority of Bacteria and Archaea may be characterized with an exterior cell wall 
which allows the organism to respond to environmental fluctuations.  The surface-layer (S-layer) 
consists of a paracrystalline structure with large proteins and is synthesized through self-
assembly (Avall-Jaaskelainen & Palva, 2005).  The intended function of the S-layer remains 
largely unknown, as even bacteria within the same species do not exhibit the same structure or 
the same function.  Predicted functions of the S-layer include a protective barrier against 
environmental hazards, regulation of nutrient and metabolite passage, preservation of cellular 
structure, and oversight of exterior surface recognition and cell adhesion (Beganovic et al., 
2011).  Understanding the mechanisms of the S-layer offers great insight to the functionality of 
lactobacilli. 
The most common electron microscopy techniques for studying the S-layer proteins of 
lactobacilli include negative staining, thin-sectioning, and freeze-etching (Avall-Jaaskelainen & 
Palva, 2005).  Under atomic force microscopy, a smooth layer may be seen with a globular layer 
of proteins on the outer surface of L. crispatus DSM20584 while a rough surface of polymeric 
surface conformations may be seen with L. helveticus ATCC 12046 and L. helveticus ATCC 
15009 (Schar-Zammaretti & Ubbink, 2003).  These exterior structural variations indicate the 
complexity and the variety of the potential S-layer functions. 
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The S-layer consists of a single, homogeneous protein species with a molecular weight 
between 40 to 71 kDa (Avall-Jaaskelainen & Palva, 2005, Engelhardt & Peters, 1998).  These 
oftentimes acidic proteins are composed of 40-60% hyrodrophobic amino acids with little to no 
sulfur-containing amino acids (Sleytr & Beveridge, 1999).  Unlike most bacterial species, the 
highly basic S-layer of lactobacilli has an isoelectric point ranging 9.35 to 10.40 (Avall-
Jaaskelainen & Palva, 2005, Smit et al., 2001, Ventura et al., 2002).  In lactobacilli, the S-layer 
may consist of 10-15% of the total cellular proteins (Boot et al., 1996b).  At this time, S-layers 
have been found in several Lactobacillus species (Table 2.1), though are not present in all 
species as L. casei and L. rhamnosus are void of this protein layer (Table 2.2).  Controversy 
surrounds L. fermentum, as no S-layer protein gene sequence exists in the public database yet 
electron microscopy revealed the presence of an S-layer (Hynonen & Palva, 2013).  This same 
phenomenon is also true for L. gasseri and L. johnsonii.  Previous reviews diverge on the 
classification of particular species (Avall-Jaaskelainen & Palva, 2005, Hollmann et al., 2010, 
Hynonen & Palva, 2013).  Improvements in genomic sequencing have expanded the capabilities 
of mining for genetic sequences associated with S-layer formation.   
The three primarily characterized S-layer proteins are SlpA, SlpB, and SlpC (Sun et al., 
2013).  In the majority of Lactobacillus cells, SlpA is highly expressed while SlpB and SlpC are 
oftentimes silent (Delcour et al., 1999).  The exposed proteins must be in the correct 
conformation in order to elicit the intended activities.  The most well understood anchoring 
region, LPXTG box, covalently binds these exterior proteins to the cell wall (Leenhouts et al., 
1999).  The C-terminal region oversees cell-wall anchoring, while the N-terminal region 
coordinates the self-assembly domain (Claus et al., 2005, Hu et al., 2011); though studies have 
also found numerous N-terminally anchored proteins (Kleerebezem et al., 2010).  The 
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coordination amongst these anchoring domains remains critical for display of the proteins on the 
cell surface.  
Though the function of the S-layer remains largely unknown, lactobacilli that require the 
crystalline protein layer do not function properly without it present.  L. acidophilus M92 
exhibited reduced adhesion to mouse ileal epithelial cells upon removal of S-layer proteins 
(Frece et al., 2005).  Attempted knock-out of L. acidophilus slpA proved unsuccessful, indicating 
necessity of the gene (Boot et al., 1996a).  In addition, attempted deletion of the ApuA gene N-
terminal repeat region was unsuccessful (Kim et al., 2009).  Removal of the S-layer in L. 
helveticus MIMlh5 resulted in decreased pro-inflammatory factors COX-2 and tumor necrosis 
factor alpha (TNF-α) induction levels in human U937 macrophages (Taverniti et al., 2013).  
Without the S-layer, cells may be more susceptible to environmental hazards due to the 
incomplete surface layer protection and inability to regulate passage of key metabolites. 
The natural self-assembly domain of the S-layer into regular arrays promotes the display 
of foreign antigens along with an immune-stimulating effect.  The potential applications of S-
layers for biotechnology include vaccine development, protein surface display, heterologous 
protein display, as well as secretion signals of S-layer protein genes (Bermudez-Humaran et al., 
2011, Hu et al., 2010, Kajikawa et al., 2012, Mercenier et al., 2000).  Foreign antigens anchored 
to the cell wall induce immune responses in animal models.  As long as a sufficient 
concentration of the foreign antigen is secreted or anchored on the cell surface, the exterior 
placement location does not impact immunogenicity.   
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Promoters 
 
Promoters initiate and regulate transcription of genes, through specification of a binding 
site for a RNA polymerase holoenzyme and a transcriptional start point.  Lactobacillus species 
vary in their promoter strengths, with the -35 and -10 hexamers and UP element as important 
factors in promoter selection (McCracken et al., 2000).  Constitutive promoters allow continuous 
transcription of the associated gene, while inducible promoters require stimulus by a substrate to 
begin transcription.  For genes under the control of the lac operator, the molecule Isopropyl β-ᴅ-
1-thiogalactopyranoside (IPTG) regulates initiation of gene expression.  The Nisin Controlled 
gene Expression system (NICE) functions by induction of the gene with sub-inhibitory levels of 
nisin added to the culture medium.  A linear dose-response curve occurs with increasing amounts 
of nisin using β-glucuronidase as the reporter gene (Mierau & Kleerebezem, 2005).  Selection of 
a native host promoter ensures recognition by the host strain. 
The strong promoters involved with S-layer synthesis are very efficient.  The constitutive 
promoter of the L. acidophilus S-layer gene is twice as efficient as the lactate dehydrogenase 
gene – one of the strongest promoters described in bacteria (Boot et al., 1996b).   Some 
lactobacilli species have multiple promoters in front of the S-layer protein gene, including 
Lactobacillus brevis which has two active adjacent promoters (Hynonen et al., 2010, Kahala & 
Palva, 1999).  For recombinant lactobacilli expressing foreign antigens, the promoter selected 
must maintain a balance between sufficient protein expression and maintenance of the exterior 
surface structure. 
Microarray analysis provides a valuable tool for identifying the expression levels of 
lactobacilli genes dependent upon carbohydrate sources.  Duong, et al. (2011) utilized 
microarray analysis to identify operons involved in the transport and catabolism of 
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fructooligosaccharides (FOS), lactose (lac), trehalose (tre), and genes directing glycolysis to 
select promoters for lactobacilli expression vectors.  The putative promoters FOS (PFOS), lac 
(Plac), and tre (Plac) were implemented into the construction of carbohydrate-induced vectors, 
while the promoter pgm (Ppgm) was selected for construction into a constitutive expression 
vector.  Results indicate that the expression systems maintained activity comparable to the native 
genes positioned in the original Lactobacillus genome, supporting the use of these promoters in 
vector systems.  Selection of the promoters greatly influences the expression level of the gene of 
interest. 
 
 
Protein Expression 
 
The manner in which the bacterial vector delivers the antigen via cellular location 
(cytoplasmic, secreted, or anchored in or on the cell wall) significantly impacts the 
immunogenicity.  Cytoplasmic localization of a protein protects it from the harsh external 
environment, though requires cell lysis for protein delivery.  Secretion of produced proteins into 
the external environment leads to direct contact with the food source, GIT, etc.  Anchoring of the 
protein (surface display) to the cell wall promotes simultaneous interaction with the environment 
and protection from proteolytic degradation.  Anchoring of the antigen to the surface of the cell 
wall produces the largest antigen immunogenicity (Bermudez-Humaran et al., 2004, Norton et 
al., 1996).  Therefore, the majority of vaccination studies should focus upon cell-wall anchored 
protein delivery, rather than cytoplasmic or secreted delivery locations. 
There are numerous options for anchoring of proteins to the lactobacilli extracellular 
surface.  Previous studies include lipid-mediated N-terminal anchoring to the cell membrane, N-
terminal anchoring to the cell membrane facilitated by a non-cleaved N-terminal signal peptide 
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(SP), C-terminal sortase-mediated covalent anchoring to the cell wall, and noncovalent 
anchoring through additional domains that directly interact with the cell wall, such as the LysM 
domain (Fredriksen et al., 2012, Hu et al., 2010).  The sortase-mediated route has received the 
greatest amount of attention (Marraffini et al., 2006, Ton-That et al., 1999).  In the case of two 
recombinant L. acidophilus strains displaying the same Salmonella flagellin (FliC) in different 
anchoring motifs, the cell surface structures displayed divergent dendritic cell maturation and 
cytokine production (Kajikawa et al., 2011).  FliC was first fused to the C-terminal region of the 
cell envelope proteinase (PrtP) and then bound to the cell wall via electrostatic bonds.  In the 
second method, FliC was conjugated to the mucus binding protein (Mub) anchoring region and 
covalently linked to the LPXTG motif of the cell wall (Kajikawa et al., 2011).  The surface-
displayed antigens were highly sensitive to gastric and small intestine secretions, diminishing the 
likelihood of oral administration of this recombinant strain as it may not survive the harsh 
environment of the stomach and small intestine.   
Strain variations amongst lactobacilli impact the quantity of expressed antigen.  The 
method of antigen presentation on the cellular surface, especially between species, may elicit 
different immunogenic responses between lactobacilli.  Thus, when selecting lactobacilli strains 
the expressed antigen concentration must be evaluated in vitro before inoculation in vivo with 
subsequent analysis of the host serum.  Western Blotting results indicate a clear visual if the 
antigen is present, though do require a specifically designed antibody for detection.  Flow-
cytometric analysis offers an additional form of recognition, utilizing fluorescent proteins which 
pass through an electronic detector (Kajikawa et al., 2011).  As previously stated, the promoter 
expression and secretion of the protein across the cell membrane influence the level of antigen 
expression.   
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Adjuvants 
 
As gram-positive bacteria, lactobacilli have intrinsic adjuvant properties to induce either 
a proinflammatory or regulatory immune response both in vitro and in vivo.  Lactobacillus 
strains present microbe-associated molecular patterns (MAMPS) which include lipoproteins, 
lipoteichoic acids (LTA), peptidoglycan (PG), and muramyl dipeptide (MDP) which in turn are 
recognized by Toll-like receptor (TLR) 2, TLR 6, and nucleotide-binding oligomerization 
domain 2 (NOD2) (Lebeer et al., 2010, Stoeker et al., 2011).  Due to the absence of flagella 
these strains lack the ability to elicit a TLR5 response. 
Within a host, adjuvants enhance the ability of the immune system to respond to an 
antigen.  While intrinsic adjuvants exist, vaccines co-administered with an adjuvant are 
characterized by increasing uptake by or stimulating DCs and macrophages.  Bacterial flagellin 
proteins fused with other antigens act as an adjuvant, potentially due to the activation of NF-κB 
via TLR5 and caspase-1 inflammasome through Nod-like receptor Caspase recruitment domain 4 
(NLRC4) (Fredriksen et al., 2012).  Intragastric immunization of mice with L. acidophilus 
displaying Gag and S. enterica ser. Typhimurium flagellin (FliC) resulted in an increase of Gag-
specific IgA-secreting cells; indicating the presence of FliC resulted in an adjuvant effect on 
local IgA production (Kajikawa et al., 2012).  The intended in vivo immune response must be 
confirmed before selection of an adjuvant, as the immune systems of various animal species 
differ in their ability to detect particular stimulations. 
 
 
2.4 Selection of Probiotic Strains in the Poultry Industry 
 
To qualify as a probiotic for use in the poultry industry, the strain must be a natural 
inhabitant of the GIT, survive low pH conditions and the presence of bile acids, adhere to the 
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intestinal epithelium, and compete with autochthonous and allochthonous organisms present 
(Ehrmann et al., 2002, Koenen et al., 2004a, Lutful Kabir, 2009, Patterson & Burkholder, 2003).  
For the potential probiotic to be endorsed in the poultry industry, it must achieve the intended 
beneficial effects while withstanding industrial processes and maintaining viability under 
prolonged storage conditions.  Upon commercialization, the probiotic may be administered via 
drinking water, feed routes, or sprayed directly onto the birds.  The probiotic would then enter 
the GIT through the oral cavity; a realistic strategy for large scale facilities that cannot 
administer hundreds of birds through oral gavage.  Poultry producers must be knowledgeable of 
the probiotic functionality and the appropriate handling requirements to ensure effective 
treatment. 
As probiotic and vaccine strategies continue to undergo rigorous in vivo testing, the 
efficacy of live oral administration relies upon three key factors – dosing, timing, and frequency.  
Animal studies require a certain degree of finesse and experience, to optimize these three factors 
for the intended strain.  The key time to administer a lactobacilli treatment-based method 
involves the lag period between the descending maternal antibodies (<3 weeks of age) and the 
increasing probability of C. jejuni colonization.  Lactobacilli require sufficient time to replicate 
within the lumen and to colonize the cecum; boosters enhance the effect of the lactobacilli.  A 
practical strategy must balance treatment timing, dosing, and frequency with the natural 
colonization of the GIT.     
 
 
Lactobacillus spp. Probiotics for Broiler Chickens 
 
Human pathogens associated with raw and undercooked poultry products include S. 
enterica ser. Enteritidis and C. jejuni.  Current practices (eg. antibiotics, vaccination, 
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modification of diet, feed additives, prebiotics, and control of biosecurity) are not sufficient for 
total eradication of these pathogens from the poultry facility and outbreaks persist throughout the 
United States.  The mucosal layer of the GI epithelium inhibits invasion of pathogenic bacteria 
and foreign compounds through a chemical and physical barrier, while allowing normal activity 
of commensal bacteria (Bron et al., 2011).  To successfully invade this layer, pathogenic bacteria 
adhere and penetrate the protective layer to invade enterocytes which may result in clinical 
infection (Koutsos & Arias, 2006).  Through prevention of pathogenic bacteria adhesion and 
penetration of the mucosal layer, the rate of infection may be reduced.    
Upon survival through the gastric environment of the stomach and escaping from bile 
salts, probiotics now face the challenge of the epithelial mucosal layer.  The intestinal mucosa is 
composed of a nutrient rich, one-cell-thick layer, which rests on a sub-layer of enterocytes that 
sample the environment with follicles (Bron et al., 2011).  The peristaltic motion of the intestine 
moves bacteria, nutrients, and waste through the lumen (Abreu, 2010).  To maintain a presence, 
probiotics must adhere to glycans on the mucosal layer long enough to impart the predicted 
beneficial effects.  Adherence to the epithelial lining of the GIT and an inability to be easily 
removed promotes colonization. 
As previously discussed, dosage of probiotics into the GIT of broiler chickens offers 
numerous mechanistic advantages for control of pathogens and benefits to host health.  Farmers 
have already adopted the usage of probiotics, which reduce abdominal fat deposition, improve 
body weight gain, improve feed conversion rate, and control intestinal human pathogens 
(Kalavathy et al., 2003, Schneitz, 2005).  Probiotics and prebiotics fed to broiler chickens 
decrease E. coli and total aerobic populations while increasing cecal volatile fatty acids and non-
VFA concentrations (Mookiah et al., 2014).  Probiotics have been shown to be growth promoters 
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in broiler chickens (Kalavathy et al., 2008, Mountzouris et al., 2007, Mountzouris et al., 2010).  
The most commonly used probiotics for livestock and poultry include Lactobacillus, 
Enterococcus, Bacillus, and Saccharomyces (Gaggia et al., 2010).  As there remains great debate 
on the efficacy of these probiotics, the results vary greatly by probiotic strain, concentration of 
dose, timing, host breed, and age of the host (Koenen et al., 2004b, La Ragione et al., 2004).  
Further investigations are needed to explore the appropriate timing of probiotic dosage along 
with application in a commercial setting, rather than a controlled experimental model. 
Animal studies indicate the ability of lactobacilli to prevent colonization of human 
pathogens.  When co-administered with S. enterica serovar Enteritidis C-114 by oral gavage in 
broiler chickens, L. salivarius was found to prevent pathogen colonization.  A follow-up feed 
study indicated a secondary dose would be needed to ensure the presence of the probiotic at the 
time of poultry harvest (Pascual et al., 1999).  A combination of L. acidophilus and L. fermentum 
inhibited the adhesion of pathogenic Salmonella to the chicken mucosal layer in vitro, a stronger 
effect then administering each strain individually (Ma et al., 2006).  Multistrain (or multispecies) 
probiotics may be more successful in reducing pathogen adhesion than monostrain treatments 
(Timmerman et al., 2004).  Further studies are investigating the efficacy of these lactobacilli 
strains in preventing C. jejuni colonization. 
For in vivo studies, the primary source of the lactobacilli strain impacts the colonization 
within the GIT.  Strains isolated from the equivalent animal model increase the likelihood of 
colonization and proliferation in the intended luminal location (Chen et al., 2012).  Ma, et al. 
(2006) found that Lactobacillus strains from the cecum indicated greater adhesion in vitro to the 
mucosal layer of the ileum, cecum, and colon than to that of the duodenum and jejunum.  The 
composition of the mucosal layer impacts the specific bacteria that adhere.  Initially, 
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identification of potential strains occurs in vitro with selection by survival factors such as 
withstanding low pH, bile acids, host enzymatic and hydrolytic reactions, low generation time, as 
well as genetic stability (Gaggia et al., 2010).  While these factors do not guarantee the 
prolonged colonization of the probiotic, there exists an increased probability of survival through 
the GIT and production of subsequent beneficial effects. 
 
 
Lactobacillus spp. Vaccines for Broiler Chickens 
 
A promising application of lactobacilli is their use as a live vaccine, for presentation of 
DNA or proteins to the GI mucosal surfaces (Wells, 2011).  In this approach, synthesis of 
antigens by the host machinery overcomes problems such as incorrect protein folding and 
glycosylation.  The VP2 and VP3 antigens of infectious bursal disease virus (IBDV) were 
produced by recombinant Lactococcus lactis strains (Dieye et al., 2003).  The lactococcal strains 
producing staphylococcal nuclease Nuc fused to VP2 (Nuc-VP2) and VP3 were orally 
administered to chickens.  Those bacteria producing the Nuc-VP2 complex induced a systemic 
and specific immune response against Nuc but not against VP2.  Vaccinated chickens did not 
indicate a detectable immune response against VP2 and VP3.  Further research must explore the 
role of the cell-wall anchoring site and expression level required for a detectable immune 
response.   
An alternate study expressed the foreign highly pathogenic avian influenza (HPAI) 
protein, hemagglutinin 1 (HA1), with recombinant Lactobacillus delbrueckii ssp. Lactis D17 
(LDL17-pH) orally administered to broiler chickens (Wang et al., 2013).  The LDL17-pH 
triggered a mucosal and systemic immune response, indicated by increased specific anti-HA1 
IgA antibody levels in the mucosa and the anti-HA1 IgG level in sera.  Vaccinated chickens had a 
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higher survival rate, compared to the control group, when challenged with a lethal dose of H5N1 
virus.  This study demonstrated the feasibility of recombinant Lactobacillus as a candidate for 
oral administration of avian influenza virus vaccine. 
Vaccine applications may also exploit the noncovalent binding domain of LysM with the 
benefit of producing non-genetically modified organisms (GMO).  The AcmA binding domains 
of L. lactis displayed the VP1 protein of chicken anemia virus (CAV) on the surface of L. 
acidophilus (Moeini et al., 2011).  After verification of the binding of the CAV VP1 protein on 
the bacterial cell surface, broiler chickens were orally gavaged with the lactobacilli cells carrying 
the VP1 protein.  Evaluation of vaccinated birds indicated increased levels of Th1 cytokines 
interleukin (IL)-2, IL-12, and IFN-γ.  This strategy indicates the potential of L. acidophilus and 
the LysM domain to orally delivery vaccines to broiler chickens.   
A positive correlation may exist between the ability of bacteria to adhere to the chicken 
mucosal lining and the presence of an S-layer in avian isolates, such as L. acidophilus.  
Recombinant lactobacilli that express heterologous proteins manipulate this immunogenic 
recognition and prepare the host for future challenge by pathogenic organisms.  Limited research 
has evaluated the outcome of recombinant lactobacilli orally administered to broiler chickens.  
Broiler chickens orally administered Lactobacillus spp. along with microencapsulated 
recombinant FliC protein and the subunit B of cholera toxin ellicited host immune responses 
(Baptista et al., 2014).  More specifically, this strategy stimulated the humoral and cellular 
immune responses, in combination with altering the population of CD8
+
 T lymphocytes in the 
cecum.  Existing vaccine strategies are capable of eliciting a cell-mediated immune response and 
systemic antibody-immune response (Brisbin et al., 2011); though require a booster or multiple 
doses to effectively evoke an adaptive immune response in the host.   
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Challenging a broiler chicken with a recombinant vaccine prepares the immune system 
for future interactions with a specific infectious organism.  Thus, the host responds sooner, with 
a large repertoire of antibody molecules to recognize the infectious antibodies.  While the host-
produced antibodies target the foreign antigen, these antibodies also interact with host receptors 
to eliminate the antigen and to promote the activation of the immune response.  A vaccination 
approach must overcome the antigen variances between strains, an incomplete knowledge of 
inducing a protective immune response, and provide protection against pathogens early in the 
physical development of the bird (Wagenaar et al., 2006).  Utilization of both a probiotic and 
vaccination approach combines the relative mechanisms for administration in vivo. 
Molecular biology techniques utilize cloning vectors for heterologous protein expression.  
These tools improve the ease of studying genes of interest from prokaryotes and eukaryotes.  
Typically an engineered plasmid contains a (i) multiple cloning site (MCS), (ii) antibiotic 
resistance marker, and (iii) an origin of replication (ori).  When selecting a vector, important 
factors to consider include copy number, size of the insert, and the type of promoter (constitutive 
or inducible).      
 
 
2.5 Future Direction 
 
Present research indicates that treatment with lactobacilli probiotics and vaccines results 
in incomplete elimination of pathogen colonization, though the reduction in pathogens will 
presumably decrease the probability of human health consequences.  The future implementation 
of lactobacilli probiotic and vaccine strategies largely depends upon commercialization and 
administration costs, dosage operation in production facilities, acceptance of GMOs by 
regulatory standards, and efficacy of strains.  To achieve success in the poultry industry, these 
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novel protection strategies must offer greater benefits than the present routes of administration 
and achieve a higher degree of efficacy to compensate for the increased cost of animal care. 
 
2.6 References 
Abreu M. T. (2010). Toll-like receptor signalling in the intestinal epithelium: How bacterial 
recognition shapes intestinal function. Nat Rev Immunol 10, 131-144. 
Allen V. M., Weaver H., Ridley A. M., Harris J. A., Sharma M., Emery J., Sparks N., Lewis 
M., Edge S. (2008). Sources and spread of thermophilic Campylobacter spp. during partial 
depopulation of broiler chicken flocks. J Food Prot 71, 264-270. 
Anadon A., Martinez-Larranaga M. R., Aranzazu Martinez M. (2006). Probiotics for animal 
nutrition in the European Union. regulation and safety assessment. Regul Toxicol Pharmacol 45, 
91-95. 
Annamalai T., Pina-Mimbela R., Kumar A., Binjawadagi B., Liu Z., Renukaradhya G. J., 
Rajashekara G. (2013). Evaluation of nanoparticle-encapsulated outer membrane proteins for 
the control of Campylobacter jejuni colonization in chickens. Poult Sci 92, 2201-2211. 
Avall-Jaaskelainen S. & Palva A. (2005). Lactobacillus surface layers and their applications. 
FEMS Microbiol Rev 29, 511-529. 
Baptista A. A., Donato T. C., Garcia K. C., Goncalves G. A., Coppola M. P., Okamoto A. 
S., Sequeira J. L., Andreatti Filho R. L. (2014). Immune response of broiler chickens 
immunized orally with the recombinant proteins flagellin and the subunit B of cholera toxin 
associated with Lactobacillus spp. Poult Sci 93, 39-45. 
Batz M. B., Hoffman S., Morris J. G. (2011). Ranking the risks: The 10 pathogen-food 
combinations with the greatest burden on public health. Univ Flor Emer Path Inst . 
Beery J. T., Hugdahl M. B., Doyle M. P. (1988). Colonization of gastrointestinal tracts of 
chicks by Campylobacter jejuni. Appl Environ Microbiol 54, 2365-2370. 
Beganovic J., Frece J., Kos B., Lebos Pavunc A., Habjanic K., Suskovic J. (2011). 
Functionality of the S-layer protein from the probiotic strain Lactobacillus helveticus M92. 
Antonie Van Leeuwenhoek 100, 43-53. 
Bermudez-Humaran L. G., Kharrat P., Chatel J. M., Langella P. (2011). Lactococci and 
lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines. Microb Cell 
Fact 10 Suppl 1, S4-2859-10-S1-S4. Epub 2011 Aug 30. 
27 
 
Bermudez-Humaran L. G., Cortes-Perez N. G., Le Loir Y., Alcocer-Gonzalez J. M., 
Tamez-Guerra R. S., de Oca-Luna R. M., Langella P. (2004). An inducible surface 
presentation system improves cellular immunity against Human Papillomavirus Type 16 E7 
antigen in mice after nasal administration with recombinant lactococci. J Med Microbiol 53, 427-
433. 
Bernardeau M., Vernoux J. P., Henri-Dubernet S., Gueguen M. (2008). Safety assessment of 
dairy microorganisms: The Lactobacillus genus. Int J Food Microbiol 126, 278-285. 
Boot H. J., Kolen C. P., Pouwels P. H. (1996a). Interchange of the active and silent S-layer 
protein genes of Lactobacillus acidophilus by inversion of the chromosomal slp segment. Mol 
Microbiol 21, 799-809. 
Boot H. J., Kolen C. P., Pouwels P. H. (1995). Identification, cloning, and nucleotide sequence 
of a silent S-layer protein gene of Lactobacillus acidophilus ATCC 4356 which has extensive 
similarity with the S-layer protein gene of this species. J Bacteriol 177, 7222-7230. 
Boot H. J., Kolen C. P., Andreadaki F. J., Leer R. J., Pouwels P. H. (1996b). The 
Lactobacillus acidophilus S-layer protein gene expression site comprises two consensus 
promoter sequences, one of which directs transcription of stable mRNA. J Bacteriol 178, 5388-
5394. 
Boot H. J., Kolen C. P., Pot B., Kersters K., Pouwels P. H. (1996c). The presence of two S-
layer-protein-encoding genes is conserved among species related to Lactobacillus acidophilus. 
Microbiology 142 ( Pt 9), 2375-2384. 
Borchers A. T., Selmi C., Meyers F. J., Keen C. L., Gershwin M. E. (2009). Probiotics and 
immunity. J Gastroenterol 44, 26-46. 
Brisbin J. T., Gong J., Orouji S., Esufali J., Mallick A. I., Parvizi P., Shewen P. E., Sharif S. 
(2011). Oral treatment of chickens with lactobacilli influences elicitation of immune responses. 
Clin Vaccine Immunol 18, 1447-1455. 
Bron P. A., van Baarlen P., Kleerebezem M. (2011). Emerging molecular insights into the 
interaction between probiotics and the host intestinal mucosa. Nat Rev Microbiol 10, 66-78. 
Buckley A. M., Wang J., Hudson D. L., Grant A. J., Jones M. A., Maskell D. J., Stevens M. 
P. (2010). Evaluation of live-attenuated Salmonella vaccines expressing Campylobacter antigens 
for control of C. jejuni in poultry. Vaccine 28, 1094-1105. 
Callegari M. L., Riboli B., Sanders J. W., Cocconcelli P. S., Kok J., Venema G., Morelli L. 
(1998). The S-layer gene of Lactobacillus helveticus CNRZ 892: Cloning, sequence and 
heterologous expression. Microbiology 144 ( Pt 3), 719-726. 
Cawthraw S. A. & Newell D. G. (2010). Investigation of the presence and protective effects of 
maternal antibodies against Campylobacter jejuni in chickens. Avian Dis 54, 86-93. 
28 
 
Chen C. Y., Tsen H. Y., Lin C. L., Yu B., Chen C. S. (2012). Oral administration of a 
combination of select Lactic Acid Bacteria strains to reduce the Salmonella invasion and 
inflammation of broiler chicks. Poult Sci 91, 2139-2147. 
Christensen H. R., Frokiaer H., Pestka J. J. (2002). Lactobacilli differentially modulate 
expression of cytokines and maturation surface markers in murine dendritic cells. J Immunol 
168, 171-178. 
Christensen J. E., Pacheco S. A., Konkel M. E. (2009). Identification of a Campylobacter 
jejuni-secreted protein required for maximal invasion of host cells. Mol Microbiol 73, 650-662. 
Claus H., Akca E., Debaerdemaeker T., Evrard C., Declercq J. P., Harris J. R., Schlott B., 
Konig H. (2005). Molecular organization of selected prokaryotic S-layer proteins. Can J 
Microbiol 51, 731-743. 
Degnan F. H. (2008). The US Food and Drug Administration and probiotics: Regulatory 
categorization. Clin Infect Dis 46 Suppl 2, S133-6; discussion S144-51. 
Delcour J., Ferain T., Deghorain M., Palumbo E., Hols P. (1999). The biosynthesis and 
functionality of the cell-wall of Lactic Acid Bacteria. Antonie Van Leeuwenhoek 76, 159-184. 
Detmer A. & Glenting J. (2006). Live bacterial vaccines--a review and identification of 
potential hazards. Microb Cell Fact 5, 23. 
Dieye Y., Hoekman A. J., Clier F., Juillard V., Boot H. J., Piard J. C. (2003). Ability of 
Lactococcus lactis to export viral capsid antigens: A crucial step for development of live 
vaccines. Appl Environ Microbiol 69, 7281-7288. 
Duong T. (2011). Vaccines and anti-infective agents: Delivery via Lactic Acid Bacteria. 
Encyclopedia of Biotechnology in Agriculture and Food 13, 664-667. 
Duong T., Miller M. J., Barrangou R., Azcarate-Peril M. A., Klaenhammer T. R. (2011). 
Construction of vectors for inducible and constitutive gene expression in Lactobacillus. Microb 
Biotechnol 4, 357-367. 
EFSA. (2007). Introduction of a Qualified Presumption of Safety (QPS) approach for assessment 
of selected microorganisms referred to EFSA Opinion of the Scientific Committee (Question No 
EFSA-Q-2005-293) Adopted on 19 November 2007. EFSA J 587, 1-16. 
Ehrmann M. A., Kurzak P., Bauer J., Vogel R. F. (2002). Characterization of lactobacilli 
towards their use as probiotic adjuncts in poultry. J Appl Microbiol 92, 966-975. 
Engelhardt H. & Peters J. (1998). Structural research on surface layers: A focus on stability, 
surface layer homology domains, and surface layer-cell wall interactions. J Struct Biol 124, 276-
302. 
29 
 
Flanagan R. C., Neal-McKinney J. M., Dhillon A. S., Miller W. G., Konkel M. E. (2009). 
Examination of Campylobacter jejuni putative adhesins leads to the identification of a new 
protein, designated FlpA, required for chicken colonization. Infect Immun 77, 2399-2407. 
Fooks L. J. & Gibson G. R. (2002). Probiotics as modulators of the gut flora. Br J Nutr 88 
Suppl 1, S39-49. 
Frece J., Kos B., Svetec I. K., Zgaga Z., Mrsa V., Suskovic J. (2005). Importance of S-layer 
proteins in probiotic activity of Lactobacillus acidophilus M92. J Appl Microbiol 98, 285-292. 
Fredriksen L., Kleiveland C. R., Hult L. T., Lea T., Nygaard C. S., Eijsink V. G., 
Mathiesen G. (2012). Surface display of N-terminally anchored invasin by Lactobacillus 
plantarum activates NF-κB in monocytes. Appl Environ Microbiol 78, 5864-5871. 
Gaggia F., Mattarelli P., Biavati B. (2010). Probiotics and prebiotics in animal feeding for safe 
food production. Int J Food Microbiol 141 Suppl 1, S15-28. 
Garrote G. L., Delfederico L., Bibiloni R., Abraham A. G., Perez P. F., Semorile L., De 
Antoni G. L. (2004). Lactobacilli isolated from kefir grains: Evidence of the presence of S-layer 
proteins. J Dairy Res 71, 222-230. 
Godschalk P. C., Heikema A. P., Gilbert M., Komagamine T., Ang C. W., Glerum J., 
Brochu D., Li J., Yuki N.& other authors. (2004). The crucial role of Campylobacter jejuni 
genes in anti-ganglioside antibody induction in Guillain-Barré Syndrome. J Clin Invest 114, 
1659-1665. 
Golowczyc M. A., Mobili P., Garrote G. L., Abraham A. G., De Antoni G. L. (2007). 
Protective action of Lactobacillus kefir carrying S-layer protein against Salmonella enterica 
serovar Enteritidis. Int J Food Microbiol 118, 264-273. 
Hagen K. E., Guan L. L., Tannock G. W., Korver D. R., Allison G. E. (2005). Detection, 
characterization, and in vitro and in vivo expression of genes encoding S-proteins in 
Lactobacillus gallinarum strains isolated from chicken crops. Appl Environ Microbiol 71, 6633-
6643. 
Ham J. S., Kim H. W., Seol K. H., Jang A., Jeong S. G., Oh M. H., Kim D. H., Kang D. K., 
Kim G. B., Cha C. J. (2011). Genome sequence of Lactobacillus salivarius NIAS840, isolated 
from chicken intestine. J Bacteriol 193, 5551-5552. 
Havenith C. E. G., Seegers J. F. M. L., Pouwels P. H. (2002). Gut-associated lactobacilli for 
oral immunisation. Food Res Int 35, 151-163. 
Hermans D., Van Deun K., Martel A., Van Immerseel F., Messens W., Heyndrickx M., 
Haesebrouck F., Pasmans F. (2011a). Colonization factors of Campylobacter jejuni in the 
chicken gut. Vet Res 42, 82-9716-42-82. 
30 
 
Hermans D., Pasmans F., Messens W., Martel A., Van Immerseel F., Rasschaert G., 
Heyndrickx M., Van Deun K., Haesebrouck F. (2012). Poultry as a host for the zoonotic 
pathogen Campylobacter jejuni. Vector Borne Zoonotic Dis 12, 89-98. 
Hermans D., Van Deun K., Messens W., Martel A., Van Immerseel F., Haesebrouck F., 
Rasschaert G., Heyndrickx M., Pasmans F. (2011b). Campylobacter control in poultry by 
current intervention measures ineffective: Urgent need for intensified fundamental research. Vet 
Microbiol 152, 219-228. 
Hollmann A., Delfederico L., Miyoshi A., Disalvo E. A., De Antoni G., Semorile L., Azevedo 
V. (2010). S-layer proteins from lactobacilli as vaccine delivery systems. Int  J  Microbiol  Res 2, 
30-43. 
Hu S., Kong J., Kong W., Guo T., Ji M. (2010). Characterization of a novel LysM domain 
from Lactobacillus fermentum bacteriophage endolysin and its use as an anchor to display 
heterologous proteins on the surfaces of Lactic Acid Bacteria. Appl Environ Microbiol 76, 2410-
2418. 
Hu S., Kong J., Sun Z., Han L., Kong W., Yang P. (2011). Heterologous protein display on 
the cell surface of Lactic Acid Bacteria mediated by the S-layer protein. Microb Cell Fact 10, 
86-2859-10-86. 
Hughes R. A. & Cornblath D. R. (2005). Guillain-Barré Syndrome. Lancet 366, 1653-1666. 
Humphrey T., O'Brien S., Madsen M. (2007). Campylobacters as zoonotic pathogens: A food 
production perspective. Int J Food Microbiol 117, 237-257. 
Hynonen U. & Palva A. (2013). Lactobacillus surface layer proteins: Structure, function and 
applications. Appl Microbiol Biotechnol 97, 5225-5243. 
Hynonen U., Avall-Jaaskelainen S., Palva A. (2010). Characterization and separate activities 
of the two promoters of the Lactobacillus brevis S-layer protein gene. Appl Microbiol Biotechnol 
87, 657-668. 
Ivanov I. I. & Honda K. (2012). Intestinal commensal microbes as immune modulators. Cell 
Host Microbe 12, 496-508. 
Jakava-Viljanen M. & Palva A. (2007). Isolation of surface (S) layer protein carrying 
Lactobacillus species from porcine intestine and faeces and characterization of their adhesion 
properties to different host tissues. Vet Microbiol 124, 264-273. 
Jay J., Loessner M., Golden D. (2005). Modern Food Microbiology. New York, NY: Springer; 
7th edition. 
Jones K. (2001). Campylobacters in water, sewage and the environment. Symp Ser Soc Appl 
Microbiol (30), 68S-79S. 
31 
 
Kahala M. & Palva A. (1999). The expression signals of the Lactobacillus brevis slpA gene 
direct efficient heterologous protein production in Lactic Acid Bacteria. Appl Microbiol 
Biotechnol 51, 71-78. 
Kajikawa A., Nordone S. K., Zhang L., Stoeker L. L., LaVoy A. S., Klaenhammer T. R., 
Dean G. A. (2011). Dissimilar properties of two recombinant Lactobacillus acidophilus strains 
displaying Salmonella FliC with different anchoring motifs. Appl Environ Microbiol 77, 6587-
6596. 
Kajikawa A., Zhang L., Long J., Nordone S., Stoeker L., LaVoy A., Bumgardner S., 
Klaenhammer T., Dean G. (2012). Construction and immunological evaluation of dual cell 
surface display of HIV-1 gag and Salmonella enterica serovar Typhimurium FliC in 
Lactobacillus acidophilus for vaccine delivery. Clin Vaccine Immunol 19, 1374-1381. 
Kalavathy R., Abdullah N., Jalaludin S., Wong C. M. V. L., Ho Y. W. (2008). Effect of 
Lactobacillus cultures and oxytetracycline on the growth performance and serum lipids of 
chickens. Int  J  Poult  Sci 7, 4, 385-389. 
Kalavathy R., Abdullah N., Jalaludin S., Ho Y. W. (2003). Effects of Lactobacillus cultures 
on growth performance, abdominal fat deposition, serum lipids and weight of organs of broiler 
chickens. Br Poult Sci 44, 139-144. 
Karlyshev A. V., Ketley J. M., Wren B. W. (2005). The Campylobacter jejuni glycome. FEMS 
Microbiol Rev 29, 377-390. 
Kim J. H., Sunako M., Ono H., Murooka Y., Fukusaki E., Yamashita M. (2009). 
Characterization of the C-terminal truncated form of amylopullulanase from Lactobacillus 
plantarum L137. J Biosci Bioeng 107, 124-129. 
Kim M., Ashida H., Ogawa M., Yoshikawa Y., Mimuro H., Sasakawa C. (2010). Bacterial 
interactions with the host epithelium. Cell Host Microbe 8, 20-35. 
Klaenhammer T. R. (1995). Genetics of intestinal lactobacilli. Int Dairy J , 1019-1058. 
Kleerebezem M., Hols P., Bernard E., Rolain T., Zhou M., Siezen R. J., Bron P. A. (2010). 
The extracellular biology of the lactobacilli. FEMS Microbiol Rev 34, 199-230. 
Koenen M. E., van der Hulst R., Leering M., Jeurissen S. H., Boersma W. J. (2004a). 
Development and validation of a new in vitro assay for selection of probiotic bacteria that 
express immune-stimulating properties in chickens in vivo. FEMS Immunol Med Microbiol 40, 
119-127. 
Koenen M. E., Kramer J., van der Hulst R., Heres L., Jeurissen S. H., Boersma W. J. 
(2004b). Immunomodulation by probiotic lactobacilli in layer- and meat-type chickens. Br Poult 
Sci 45, 355-366. 
32 
 
Konkel M. E., Larson C. L., Flanagan R. C. (2010). Campylobacter jejuni FlpA binds 
fibronectin and is required for maximal host cell adherence. J Bacteriol 192, 68-76. 
Konkel M. E., Kim B. J., Rivera-Amill V., Garvis S. G. (1999). Bacterial secreted proteins are 
required for the internaliztion of Campylobacter jejuni into cultured mammalian cells. Mol 
Microbiol 32, 691-701. 
Konkel M. E., Garvis S. G., Tipton S. L., Anderson D. E.,Jr, Cieplak W.,Jr. (1997). 
Identification and molecular cloning of a gene encoding a fibronectin-binding protein (CadF) 
from Campylobacter jejuni. Mol Microbiol 24, 953-963. 
Konkel M. E., Klena J. D., Rivera-Amill V., Monteville M. R., Biswas D., Raphael B., 
Mickelson J. (2004). Secretion of virulence proteins from Campylobacter jejuni is dependent on 
a functional flagellar export apparatus. J Bacteriol 186, 3296-3303. 
Koutsos E. A. & Arias V. J. (2006). Intestinal ecology: Interactions among the gastrointestinal 
tract, nutrition, and the microflora. J Appl  Poult  Res 15, 161-173. 
Kuwabara S. & Yuki N. (2013). Axonal Guillain-Barré Syndrome: Concepts and controversies. 
Lancet Neurol 12, 1180-1188. 
La Ragione R. M., Narbad A., Gasson M. J., Woodward M. J. (2004). In vivo 
characterization of Lactobacillus johnsonii FI9785 for use as a defined competitive exclusion 
agent against bacterial pathogens in poultry. Lett Appl Microbiol 38, 197-205. 
Layton S. L., Morgan M. J., Cole K., Kwon Y. M., Donoghue D. J., Hargis B. M., Pumford 
N. R. (2011). Evaluation of Salmonella-vectored Campylobacter peptide epitopes for reduction 
of Campylobacter jejuni in broiler chickens. Clin Vaccine Immunol 18, 449-454. 
Lebeer S., Vanderleyden J., De Keersmaecker S. C. (2010). Host interactions of probiotic 
bacterial surface molecules: Comparison with commensals and pathogens. Nat Rev Microbiol 8, 
171-184. 
Leenhouts K., Buist G., Kok J. (1999). Anchoring of proteins to Lactic Acid Bacteria. Antonie 
Van Leeuwenhoek 76, 367-376. 
Lortal S., van Heijenoort J., Gruber K., Sleytr U. B. (1992). S-layer of Lactobacillus 
helveticus ATCC 12046: Isolation, chemical characterization and re-formation after extraction 
with lithium chloride. J Gen Microbiol 138, 611-618. 
Luangtongkum T., Jeon B., Han J., Plummer P., Logue C. M., Zhang Q. (2009). Antibiotic 
resistance in Campylobacter: Emergence, transmission and persistence. Future Microbiol 4, 189-
200. 
Lutful Kabir S. M. (2009). The role of probiotics in the poultry industry. Int J Mol Sci 10, 
3531-3546. 
33 
 
Ma Y. L., Guo T., Xu Z. R., You P., Ma J. F. (2006). Effect of Lactobacillus isolates on the 
adhesion of pathogens to chicken intestinal mucus in vitro. Lett Appl Microbiol 42, 369-374. 
Magnusson J., Strom K., Roos S., Sjogren J., Schnurer J. (2003). Broad and complex 
antifungal activity among environmental isolates of Lactic Acid Bacteria. FEMS Microbiol Lett 
219, 129-135. 
Malik-Kale P., Parker C. T., Konkel M. E. (2008). Culture of Campylobacter jejuni with 
sodium deoxycholate induces virulence gene expression. J Bacteriol 190, 2286-2297. 
Marraffini L. A., Dedent A. C., Schneewind O. (2006). Sortases and the art of anchoring 
proteins to the envelopes of Gram-positive bacteria. Microbiol Mol Biol Rev 70, 192-221. 
Masuda K. & Kawata T. (1983). Distribution and chemical characterization of regular arrays in 
the cell walls of strains of the genus Lactobacillus. FEMS Microbiol Lett 20, 145-150. 
Masuda K. & Kawata T. (1981). Characterization of a regular array in the wall of Lactobacillus 
buchneri and its reattachment to the outer wall components. J Gen Microbiol 124, 81-90. 
McCracken A., Turner M. S., Giffard P., Hafner L. M., Timms P. (2000). Analysis of 
promoter sequences from Lactobacillus and Lactococcus and their activity in several 
Lactobacillus species. Arch Microbiol 173, 383-389. 
Meade K. G., Narciandi F., Cahalane S., Reiman C., Allan B., O'Farrelly C. (2009). 
Comparative in vivo infection models yield insights on early host immune response to 
Campylobacter in chickens. Immunogenetics 61, 101-110. 
Mercenier A., Muller-Alouf H., Grangette C. (2000). Lactic Acid Bacteria as live vaccines. 
Curr Issues Mol Biol 2, 17-25. 
Mierau I. & Kleerebezem M. (2005). 10 years of the nisin-controlled gene expression system 
(NICE) in Lactococcus lactis. Appl Microbiol Biotechnol 68, 705-717. 
Miles R. D., Butcher G. D., Henry P. R., Littell R. C. (2006). Effect of antibiotic growth 
promoters on broiler performance, intestinal growth parameters, and quantitative morphology. 
Poult Sci 85, 476-485. 
Moeini H., Rahim R. A., Omar A. R., Shafee N., Yusoff K. (2011). Lactobacillus acidophilus 
as a live vehicle for oral immunization against chicken anemia virus. Appl Microbiol Biotechnol 
90, 77-88. 
Montville T., Matthews K., Kniel K. (2012). Chapter 9: Campylobacter Species. In Food 
Microbiology: An Introduction.  pp. 133. USA: ASM Press. 
34 
 
Mookiah S., Sieo C. C., Ramasamy K., Abdullah N., Ho Y. W. (2014). Effects of dietary 
prebiotics, probiotic and synbiotics on performance, caecal bacterial populations and caecal 
fermentation concentrations of broiler chickens. J Sci Food Agric 94, 341-348. 
Mountzouris K. C., Tsirtsikos P., Kalamara E., Nitsch S., Schatzmayr G., Fegeros K. 
(2007). Evaluation of the efficacy of a probiotic containing Lactobacillus, Bifidobacterium, 
Enterococcus, and Pediococcus strains in promoting broiler performance and modulating cecal 
microflora composition and metabolic activities. Poult Sci 86, 309-317. 
Mountzouris K. C., Tsitrsikos P., Palamidi I., Arvaniti A., Mohnl M., Schatzmayr G., 
Fegeros K. (2010). Effects of probiotic inclusion levels in broiler nutrition on growth 
performance, nutrient digestibility, plasma immunoglobulins, and cecal microflora composition. 
Poult Sci 89, 58-67. 
Nachamkin I., Allos B. M., Ho T. (1998). Campylobacter species and Guillain-Barre 
Syndrome. Clin Microbiol Rev 11, 555-567. 
Nannapaneni R., Story R., Wiggins K. C., Johnson M. G. (2005). Concurrent quantitation of 
total Campylobacter and total ciprofloxacin-resistant Campylobacter loads in rinses from retail 
raw chicken carcasses from 2001 to 2003 by direct plating at 42 degrees C. Appl Environ 
Microbiol 71, 4510-4515. 
Neal-McKinney J. M., Lu X., Duong T., Larson C. L., Call D. R., Shah D. H., Konkel M. E. 
(2012). Production of organic acids by probiotic lactobacilli can be used to reduce pathogen load 
in poultry. PLoS One 7, e43928. 
Norton P. M., Brown H. W., Wells J. M., Macpherson A. M., Wilson P. W., Le Page R. W. 
(1996). Factors affecting the immunogenicity of tetanus toxin fragment C expressed in 
Lactococcus lactis. FEMS Immunol Med Microbiol 14, 167-177. 
Nyati K. K. & Nyati R. (2013). Role of Campylobacter jejuni infection in the pathogenesis of 
Guillain-Barré Syndrome: An update. Biomed Res Int 2013, 852195. 
Ojala T., Kuparinen V., Koskinen J. P., Alatalo E., Holm L., Auvinen P., Edelman S., 
Westerlund-Wikstrom B., Korhonen T. K., Paulin L., Kankainen M. (2010). Genome 
sequence of Lactobacillus crispatus ST1. J Bacteriol 192, 3547-3548. 
Parkhill J., Wren B. W., Mungall K., Ketley J. M., Churcher C., Basham D., Chillingworth 
T., Davies R. M., Feltwell T.& other authors. (2000). The genome sequence of the food-borne 
pathogen Campylobacter jejuni reveals hypervariable sequences. Nature 403, 665-668. 
Pascual M., Hugas M., Badiola J. I., Monfort J. M., Garriga M. (1999). Lactobacillus 
salivarius CTC2197 prevents Salmonella [enterica serovar] Enteritidis colonization in chickens. 
Appl Environ Microbiol 65, 4981-4986. 
35 
 
Patterson J. A. & Burkholder K. M. (2003). Application of prebiotics and probiotics in poultry 
production. Poult Sci 82, 627-631. 
Rice B. E., Rollins D. M., Mallinson E. T., Carr L., Joseph S. W. (1997). Campylobacter 
jejuni in broiler chickens: Colonization and humoral immunity following oral vaccination and 
experimental infection. Vaccine 15, 1922-1932. 
Sahin O., Luo N., Huang S., Zhang Q. (2003). Effect of Campylobacter-specific maternal 
antibodies on Campylobacter jejuni colonization in young chickens. Appl Environ Microbiol 69, 
5372-5379. 
Schar-Zammaretti P. & Ubbink J. (2003). The cell wall of Lactic Acid Bacteria: Surface 
constituents and macromolecular conformations. Biophys J 85, 4076-4092. 
Schneitz C. (2005). Competitive exclusion in poultry - 30 years of research. Food Cont , 657-
667. 
Siezen R. J., Tzeneva V. A., Castioni A., Wels M., Phan H. T., Rademaker J. L., 
Starrenburg M. J., Kleerebezem M., Molenaar D., van Hylckama Vlieg J. E. (2010). 
Phenotypic and genomic diversity of Lactobacillus plantarum strains isolated from various 
environmental niches. Environ Microbiol 12, 758-773. 
Sillanpaa J., Martinez B., Antikainen J., Toba T., Kalkkinen N., Tankka S., Lounatmaa K., 
Keranen J., Hook M.& other authors. (2000). Characterization of the collagen-binding S-layer 
protein CbsA of Lactobacillus crispatus. J Bacteriol 182, 6440-6450. 
Sleytr U. B. & Beveridge T. J. (1999). Bacterial S-layers. Trends Microbiol 7, 253-260. 
Smit E., Oling F., Demel R., Martinez B., Pouwels P. H. (2001). The S-layer protein of 
Lactobacillus acidophilus ATCC 4356: Identification and characterisation of domains 
responsible for S-protein assembly and cell wall binding. J Mol Biol 305, 245-257. 
Smith K. E., Besser J. M., Hedberg C. W., Leano F. T., Bender J. B., Wicklund J. H., 
Johnson B. P., Moore K. A., Osterholm M. T. (1999). Quinolone-resistant Campylobacter 
jejuni infections in Minnesota, 1992-1998. investigation team. N Engl J Med 340, 1525-1532. 
Stoeker L., Nordone S., Gunderson S., Zhang L., Kajikawa A., LaVoy A., Miller M., 
Klaenhammer T. R., Dean G. A. (2011). Assessment of Lactobacillus gasseri as a candidate 
oral vaccine vector. Clin Vaccine Immunol 18, 1834-1844. 
Sun Z., Kong J., Hu S., Kong W., Lu W., Liu W. (2013). Characterization of a S-layer protein 
from Lactobacillus crispatus K313 and the domains responsible for binding to cell wall and 
adherence to collagen. Appl Microbiol Biotechnol 97, 1941-1952. 
Tarahomjoo S. (2012). Development of vaccine delivery vehicles based on Lactic Acid 
Bacteria. Mol Biotechnol 51, 183-199. 
36 
 
Taverniti V., Stuknyte M., Minuzzo M., Arioli S., De Noni I., Scabiosi C., Cordova Z. M., 
Junttila I., Hamalainen S.& other authors. (2013). S-layer protein mediates the stimulatory 
effect of Lactobacillus helveticus MIMLh5 on innate immunity. Appl Environ Microbiol 79, 
1221-1231. 
Timmerman H. M., Koning C. J., Mulder L., Rombouts F. M., Beynen A. C. (2004). 
Monostrain, multistrain and multispecies probiotics--A comparison of functionality and efficacy. 
Int J Food Microbiol 96, 219-233. 
Ton-That H., Liu G., Mazmanian S. K., Faull K. F., Schneewind O. (1999). Purification and 
characterization of sortase, the transpeptidase that cleaves surface proteins of Staphylococcus 
aureus at the LPXTG motif. Proc Natl Acad Sci U S A 96, 12424-12429. 
Ventura M., Jankovic I., Walker D. C., Pridmore R. D., Zink R. (2002). Identification and 
characterization of novel surface proteins in Lactobacillus johnsonii and Lactobacillus gasseri. 
Appl Environ Microbiol 68, 6172-6181. 
Wagenaar J. A., Mevius D. J., Havelaar A. H. (2006). Campylobacter in primary animal 
production and control strategies to reduce the burden of human campylobacteriosis. Rev Sci 
Tech 25, 581-594. 
Wang B., Wei H., Yuan J., Li Q., Li Y., Li N., Li J. (2008). Identification of a surface protein 
from Lactobacillus reuteri JCM1081 that adheres to porcine gastric mucin and human 
enterocyte-like HT-29 cells. Curr Microbiol 57, 33-38. 
Wang Z., Yu Q., Fu J., Liang J., Yang Q. (2013). Immune responses of chickens inoculated 
with recombinant Lactobacillus expressing the haemagglutinin of the avian influenza virus. J 
Appl Microbiol . 
Wells J. (2011). Mucosal vaccination and therapy with genetically modified Lactic Acid 
Bacteria. Annu Rev Food Sci Technol 2, 423-445. 
Widders P. R., Thomas L. M., Long K. A., Tokhi M. A., Panaccio M., Apos E. (1998). The 
specificity of antibody in chickens immunised to reduce intestinal colonisation with 
Campylobacter jejuni. Vet Microbiol 64, 39-50. 
Wigley P. (2013). Immunity to bacterial infection in the chicken. Dev Comp Immunol 41, 413-
417. 
Wong T. L., Hollis L., Cornelius A., Nicol C., Cook R., Hudson J. A. (2007). Prevalence, 
numbers, and subtypes of Campylobacter jejuni and Campylobacter coli in uncooked retail meat 
samples. J Food Prot 70, 566-573. 
Young K. T., Davis L. M., Dirita V. J. (2007). Campylobacter jejuni: Molecular biology and 
pathogenesis. Nat Rev Microbiol 5, 665-679. 
37 
 
Yuki N. & Odaka M. (2005). Ganglioside mimicry as a cause of Guillain-Barré Syndrome. 
Curr Opin Neurol 18, 557-561. 
Zhang W., Wang H., Liu J., Zhao Y., Gao K., Zhang J. (2013). Adhesive ability means 
inhibition activities for Lactobacillus against pathogens and S-layer protein plays an important 
role in adhesion. Anaerobe 22, 97-103. 
Zhao C., Ge B., De Villena J., Sudler R., Yeh E., Zhao S., White D. G., Wagner D., Meng J. 
(2001). Prevalence of Campylobacter spp., Escherichia coli, and Salmonella serovars in retail 
chicken, turkey, pork, and beef from the greater Washington, D.C., area. Appl Environ Microbiol 
67, 5431-5436. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
38 
 
2.7 Tables 
 
Table 2.1 Lactobacillus species with S-layer protein genes present 
Species Strain 
Method of 
Identification 
Identified 
Proteins 
Reference 
L. acidophilus  ATCC 4356 
LMG 11469 
NCFM 
ATCC 4796 
Experimental* 
Bioinformatics 
slpA, slpB 
slpA, slpB 
(Boot et al., 1995)                                
(Hynonen & Palva, 2013)                    
L. amylolyticus DSM 11664 Bioinformatics slp (Hynonen & Palva, 2013) 
L. amylovorus LMG 9496 
LMG 13135 
Experimental slpA 
slpA 
(Boot et al., 1996c)                                      
L. brevis  ATCC 8287 
ATC 14869  
JCM 1058 
Experimental* 
 
Experimental 
slpA 
slpB, slpC, 
slpD 
(Jakava-Viljanen & Palva, 
2007) 
(Garrote et al., 2004)                          
L. buchneri ATCC 4005 
YIT 0040 
Experimental 
Experimental 
 (Masuda & Kawata, 1983) 
(Masuda & Kawata, 1981) 
L. crispatus JCM 5810 
LMG 12003 
Experimental slpA, cbsA, 
cbsB 
(Sillanpaa et al., 2000)                                 
L. gallinarum LMG 9435 
8 strains 
 
Experimental 
Experimental* 
lgsB, lgsI 
lgsA, lgsB, 
lgsC, lgsD, 
lgsE,  
lgsF,lgsG, 
lgsH, lgsI 
(Boot et al., 1996c)                        
(Hagen et al., 2005)                 
                  
L. gasseri ATCC 19992 Experimental* apf1, apf2 (Ventura et al., 2002)                                        
L. gigeriorum CRBIP 24.85 Bioinformatics slp (Hynonen & Palva, 2013) 
L. helveticus CNRZ 892 
ATCC 10797 
ATCC 12046 
ATCC 521 
Experimental* 
Experimental 
Experimental 
slpH1, 
slpH2 
(Callegari et al., 1998, Lortal 
et al., 1992, Masuda & 
Kawata, 1983)                  
L. hilgardii B706 
ATCC 8290 
Bioinformatics slp (Hynonen & Palva, 2013) 
L. johnsonii ATCC 332 
NCC 533 
ATCC 33200 
ATCC 11506 
DSM 20553 
Experimental* apf1, apf2 (Ventura et al., 2002)                                      
L. kefir 20 isolates/ 
strains 
Experimental  (Garrote et al., 2004)                          
L. kefiranofaciens ZW3 Bioinformatics slp (Hynonen & Palva, 2013) 
L. parakefir AGK2 8322, 
AGK2 8328, 
JCM 8573 
 
Experimental 
 (Garrote et al., 2004)                          
L. reuteri 7 strains Bioinformatics  (Zhang et al., 2013)                     
L. salivarius 5 strains Bioinformatics  (Zhang et al., 2013)                     
* Experimental methods included sequencing as component of protein identification 
 
  
39 
 
Table 2.2 Lactobacillus species without S-layer protein genes present 
Species Strain 
Method of 
Identification 
Absent 
Proteins** 
Reference 
L. amylophilus  Bioinformatics slpA, slpB NCBI Search
2
 
L. casei  Bioinformatics  (Hynonen & Palva, 
2013) 
L. delbrueckii ssp. 
bulgaricus 
 Bioinformatics slpA (Hynonen & Palva, 
2013)               
L. delbrueckii ssp. 
delbrueckii 
 Bioinformatics slpA, slpB NCBI Search
2
 
L. delbrueckii ssp. 
lactis 
 Bioinformatics slpA, slpB NCBI Search
2
 
L. fermentum NCIB 6991 
NCTC 7230 
Bioinformatics  (Hynonen & Palva, 
2013) 
L. fructosus  Bioinformatics slpA, slpB NCBI Search
2
 
L. rhamnosus GG  ATCC 53103 Bioinformatics slpA, slpB NCBI Search
3
 
L. plantarum  Bioinformatics slpA Blast Search
1
 
**Genomic databases were queried only for the proteins SlpA and SlpB.  
1
Blast Query conducted on December 19, 2012 
2
NCBI Search conducted on February 4, 2013 
3
NCBI Search conducted on May 5, 2014 
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CHAPTER 3 LACTOBACILLUS DISPLAY OF HETEROLOGOUS PROTEIN  
 
EXPRESSION 
 
 
 
3.1 Abstract  
 
As a leading foodborne pathogen in the United States, Campylobacter jejuni in retail 
poultry meat products results in a $1.3 billion annual cost of illness with over 845,000 illnesses 
estimated annually.  In humans, campylobacteriosis is characterized by undesirable abdominal 
pain, cramping, diarrhea, and in rare circumstances Guillain-Barré Syndrome.   Current 
prevention strategies focus on the reduction of commensal C. jejuni colonization of chickens at 
the farm.  The Food and Drug Administration recognizes Lactobacillus spp. as a Generally 
Recognized as Safe food additive, with a plethora of food products formulated with probiotics.  
An interesting area of research involves recombinant lactobacilli that express foreign proteins on 
the exterior cell surface.  Within the host gastrointestinal tract, C. jejuni FlpA binds fibronectin 
and is required for bacterial adherence to host intestinal cells.  The aim of this study was to 
construct recombinant Lactobacillus strains for oral delivery of vaccines against Campylobacter 
spp. and to evaluate the immunogenicity in chickens.  Lactobacillus strains were engineered to 
express C. jejuni FlpA Domain II under a promoter fused to a secretion signal with or without an 
anchoring signal from L. acidophilus NCFM.  While L. acidophilus and L. gallinarum yielded 
successful transformants, L. crispatus and L. helveticus were not easily transformed, suggesting 
strain-to-strain variations.  A non-genetically modified alternative proposes the display of foreign 
antigens on the surface of Lactobacillus through cell wall binding domains.  Additional work 
must be conducted to evaluate the exterior protein expression and in vivo antigen-immune 
response within broiler chickens.  If successful, recombinant Lactobacillus strains could be an 
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attractive candidate as a food-grade live vaccine against Campylobacter colonization.  
Furthermore, treatment at the farm reduces the introduction of Campylobacter into the retail 
market and decreases the incidence of campylobacteriosis. 
 
 
3.2 Introduction 
 
Campylobacter jejuni is the third-leading foodborne pathogen in the United States, with 
campylobacteriosis most prevalent amongst consumers exposed to raw or undercooked poultry 
products or those that handled cross-contaminated surfaces.  Consumers exposed to C. jejuni 
may experience cramping, abdominal pain, diarrhea, and in rare cases the autoimmune disease 
termed Guillain-Barré Syndrome (GBS) (Godschalk et al., 2004, Jay et al., 2005, Nyati & Nyati, 
2013).  These mechanisms have been extensively reviewed, though prevention methods for 
campylobacteriosis remain limited (Hughes & Cornblath, 2005, Kuwabara & Yuki, 2013, 
Nachamkin et al., 1998, Yuki & Odaka, 2005).   
In order to develop adequate strategies to control the colonization of this human 
pathogen, a fundamental understanding of the mechanisms responsible for colonization, 
attachment, and invasion is needed.  Several studies have outlined how chemotaxis, flagellar 
motility, exterior protein display, and iron regulation promote Campylobacter spp. passage 
through the GI lumen and colonization of the basolateral surface of the host epithelial layer 
(Hermans et al., 2011, Montville et al., 2012, Young et al., 2007).  C. jejuni attachment to the 
host mucus and epithelium is required for the initial stages of colonization.  Present on the 
surface of C. jejuni are proteins responsible for attachment to host fibronectin-binding sites, 
including Fibronectin-like protein A (FlpA) (Flanagan et al., 2009, Konkel et al., 2010).  
Translocation of C. jejuni to the basolateral surface of human epithelial cells is critical for 
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subsequent colonization and disease onset, as this prevents the host clearance of the organism 
through peristalsis and fluid flow.   
Lactic Acid Bacteria (LAB) are a taxonomically-related group of organisms, known for 
the fermentation of sugars into the primary metabolic end-product, lactic acid.  LAB are 
commensal organisms found in the gastrointestinal tract (GIT) and mucosal surfaces of animals 
and humans, as well as environmental sources (Magnusson et al., 2003, Siezen et al., 2010).  The 
Lactobacillus genera have been recognized by the Food and Drug Administration (FDA) as 
Generally Recognized As Safe (GRAS), noting the historical safety of this organism in food 
products.  In addition, Lactobacillus is a suitable probiotic and vaccine candidate due to the 
ability to survive passage of the GIT and to exert beneficial attributes to the health of the host 
(Avall-Jaaskelainen & Palva, 2005, Bernardeau et al., 2008, Borchers et al., 2009).  The reported 
benefits include production of bacteriocins and modulation of the immune system, as well as 
prevention of tissue inflammation, gastrointestinal disorders, urinary tract infections, and 
allergies. 
Lactobacilli have been genetically manipulated to express a plethora of foreign antigens.  
Expression of the recombinant proteins may result in either secretion into the extracellular matrix 
or anchoring onto the exterior bacterial cell wall.  Antigens anchored to the cell wall stimulate 
the greatest antigen immunogenic response (Bermudez-Humaran et al., 2004, Norton et al., 
1996).  Examples of protein anchoring mechanisms include lipid-mediated N-terminal anchoring 
to the cell membrane, N-terminal anchoring to the cell membrane facilitated by a non-cleaved N-
terminal signal peptide (SP), C-terminal sortase-mediated covalent anchoring to the cell wall, 
and noncovalent anchoring through domains that directly interact with the cell wall, such as the 
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LysM domain (Fredriksen et al., 2012).  Lactobacilli expression vectors that produce foreign 
antigens for exposure in the GIT are capable of stimulating the immune system. 
Previous literature has demonstrated recombinant Lactobacillus spp. as a delivery vector for 
foreign antigens.  Orally-delivered Lactobacillus vaccine strains have been developed against the 
infective bacteria Helicobacter pylori, Enterotoxigenic Escherichia coli (ETEC), Salmonella 
enterica serovar Enteritidis, Bacillus anthracis, Borrelia burgdorferi, as well as Human 
papillomavirus (HPV-16) and Rotavirus (Tarahomjoo, 2012).  Lactobacillus spp. are GRAS 
organisms and natural isolates that are thought to colonize the GIT, to persist within the host and 
impart natural adjuvant traits.  In a recent study, mice were orally immunized with Lactobacillus 
casei expressing a fragment of β-intimin (L. casei Intcv) and challenged with Citrobacter 
rodentium (Ferreira et al., 2011).  All vaccines were able to reduce C. rodentium recovered from 
feces and fecal samples indicated host production of anti-Intcv IgA.  An additional study 
demonstrated the effectiveness of recombinant Lactobacillus delbrueckii subsp. lactis D17 
expressing the highly pathogenic avian influenza (HPAI) protein, hemagglutinin 1 (HA1) (Wang 
et al., 2013).  Broiler chickens orally inoculated with a lethal dose of H5N1 virus had a higher 
survival rate when vaccinated with the HPAI.  Additionally, increased mucosal and systemic 
immune responses were measured in terms of anti-HA1 IgA antibody levels in the mucosa and 
anti-HA1 IgG levels in sera. 
Anchoring of purified proteins onto the surface of Lactobacillus through a cell wall 
binding domain offers the benefit of a non-genetically modified organism that may elicit a host 
immune response.  Several surface-associated proteins include covalently anchored proteins (N- 
or C-terminally anchored proteins, lipoproteins, and LPxTG-anchored proteins) and noncovalent 
cell wall binding domains (LysM, choline, putative peptidoglycan, S-layer proteins with SLH 
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domains, WxL, and SH3) (Kleerebezem et al., 2010).  Of great interest are the latter group, non-
covalent cell wall binding domains, which may be exploited as a non-genetically modified 
surface display system for heterologous proteins on Lactobacillus.  LysM-containing fusion 
proteins have been deeply summarized in the literature (Visweswaran et al., 2014).  This system 
has been demonstrated with the L. casei A2 bacteriophage lysin gene as a cell wall anchor 
(Ribelles et al., 2012, Ribelles et al., 2013), the L. fermentum bacteriophage LysM domain (Hu 
et al., 2010), and the cell wall binding domain of the AcmA protein (Raha et al., 2005).   
Strategies to reduce C. jejuni colonization in broiler chickens remain limited.  Our 
objective is to either anchor or secrete C. jejuni FlpA on the surface of Lactobacillus species and 
to evaluate the protein expression in vitro.  Exposure of the broiler chicken GIT to C. jejuni 
colonization-associated proteins in the GIT should stimulate the immune response of the 
chicken.  Recombinant Lactobacillus strains expressing C. jejuni FlpA will be evaluated for 
future oral gavage of broiler chickens. 
 
 
3.3 Materials and Methods 
 
Bacterial Strains and Growth Conditions 
 
Lactobacillus strains were either procured from the American Type Culture Collection or 
gifted by collaborators (Table 3.1).  All bacterial stock cultures were stored at -80°C in 12.5% 
glycerol (v/v).  Lactobacillus strains were grown in de Mann, Rogosa, Sharpe (MRS) broth 
(Difco, Sparks, MD) or on MRS supplemented with 1.5% agar (Fisher, Fair Lawn, NJ).  Cultures 
were incubated at 37°C anaerobically (Coy, Grass Lake, MI) with a gas composition of 90% 
nitrogen, 5% hydrogen, and 5% carbon dioxide.  Lactobacillus strains were grown in the 
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presence of Erythromycin (Em, 5 µg/mL) (Fisher Scientific), when needed, unless otherwise 
noted.   
Escherichia coli strains were grown aerobically at 37°C with shaking in Luria-Bertani 
(LB) broth (Difco) or on LB supplemented with 1.5% agar.  Em was supplied at a concentration 
of 150 µg/mL and Ampicillin (Fisher Scientific) was supplied at a concentration of 100 µg/mL. 
 
DNA Preparation and Manipulations 
 
E. coli plasmid DNA was isolated using the QIAprep Spin Miniprep Kit (QIAGEN, 
Valencia, CA, USA).  Electrocompetent E. coli MC1061 cells, E. coli Top10 cells, and E. coli 
BL21 (DE3) cells were prepared and transformed according to standard protocols (Appendix A, 
Appendix B).  Additional DNA manipulations were performed according to manufacturer 
procedures.  Restriction enzymes and T4 DNA Ligase were purchased from New England 
Biolabs (NEB, Ipswich, MA).  The ligation procedure followed the NEB Ligation Protocol with 
T4 DNA Ligase (M0202).  EconoTaq PLUS 2X Master Mix was purchased from Lucigen 
(Middleton, WI).  PCR primers were created using Clone Manager 9 (Sci-Ed Software, Raleigh, 
NC) and synthesized by IDT (Coralville, IA).  PCR reactions were performed according to 
standard procedures using EconoTaq PLUS 2X Master Mix (Lucigen).  The DNA Clean and 
Concentrator Kit (Zymo Research) was used to purify PCR products and the concentration of the 
DNA measured (NanoDrop
TM
 1000 Spectrophotometer, Thermo Scientific).  Gel Loading Dye 
(Blue, 6X), Supercoiled DNA Ladder, 1 kb ladder, and a 100 bp ladder were purchased from 
NEB.  The Zymoclean Gel DNA Recovery Kit (Zymo Research, Orange, CA) was used to 
isolate DNA fragments from agarose gels.  DNA sequencing was performed by the W. M. Keck 
Center (Urbana, IL). 
46 
 
Plasmid Construction 
 
Plasmids constructed or used for this study are listed in Table 3.2.  The C. jejuni 
Fibronectin-like protein A (FlpA; Cj1279c) harbors the fibronectin type II domain, which was 
identified in the GenBank database (AL111168.1).  The cassette design was structured after 
Kajikawa, et al. (2012) and utilized a lab developed vector, pMJM-8 (Figure 3.1).  Sequences of 
interest were identified from the NCBI Conserved Domains Database by previously designed 
primers (Kajikawa et al., 2012).  These primers identified the promoter region of the pgm gene 
from L. acidophilus NCFM, the region encoding the ribosome binding site of mucin-binding 
protein (Mub) from L. acidophilus NCFM (LBA 1709 and LBA 1392), the signal sequence of 
Mub (LBA 1709 and LBA 1392), the region encoding the anchor region of Mub (LBA 1709 and 
1392), and the fliC gene from S. enterica serovar Typhimurium (Figure 3.2).  C. jejuni flpA 
Domain II was selected based on fibronectin-binding activity and the sequence identified through 
the NCBI Conserved Domains Database. 
Sequences were inputted and managed utilizing the software program, Clone Manager 
(Sci-Ed Software, Cary, NC).  The cassette places C. jejuni flpA Domain II under constitutive 
promotion of the phosphoglycerate mutase promoter (Ppgm) fused to a signal peptide with or 
without an anchor motif of Mub from L. acidophilus NCFM (Figure 3.2).  The cassette contains 
Ppgm, one of the strongest promoters in lactobacilli (Duong, T., et al, 2010).  All cassette 
sequences were codon optimized based on the codon usage table of L. acidophilus ATCC 4356 
(http://www.kazusa.or.jp/codon/).   
In order to select the restriction endonucleases, the enzyme site was limited to one 
location within the multi-cloning site of the vector (enzyme site not found in insert), mandatory 
buffer activity of 100%, and affordability.  Care was taken to not select restriction endonucleases 
47 
 
with compatible ends, in order to avoid self-ligation.  In the case a restriction enzyme site was 
identified more than once between the vector and the insert and a suitable restriction enzyme 
could not be identified, codon optimization was performed.  New England Biolabs (NEB) 
restriction endonucleases were chosen to be compatible within Buffer System 4.  Restriction 
enzyme sites were manually added to the 5’ and 3’ ends of the synthesized sequences for ease of 
cloning (Figure 3.4, Figure 3.6, and Figure 3.8 – underlined).  
The pMJM-13 and pMJM-14 cassettes were synthesized and cloned via the SacII/BamHI 
sites into pMJM-8 by Genewiz, Inc. (South Plainfield, NJ).  The pMJM-15 cassette was 
synthesized and cloned via the BamHI/ApaI sites into pMJM-8 by Genewiz, Inc.  The pMJM-8 
plasmid was derived from pGK12, with a multi-cloning site (MCS) from pBluescript and an Em 
resistance gene (Figure 3.1).  The resulting vector pMJM-13 (Figure 3.3) contains the secretion 
(S1709) and anchor (A1392) signal sequences of Mub from L. acidophilus NCFM (Figure 3.4), 
while the vector pMJM-14 (Figure 3.5) contains only the secretion signal sequence of Mub 
(S1709) (Figure 3.6).  The vector pMJM-15 (Figure 3.7) contains the secretion (S1392) and the 
anchor (A1709) signal sequences of Mub along with the S. enterica serovar Typhimurium fliC 
gene (Figure 3.8).  
 
Transformation and Verification 
 
Lyophilized plasmid samples (4 µg) received from Genewiz, Inc. were spun down, 
resuspended in 20 µL molecular grade water, allowed to stand for 5-10 min on ice, vortexed, and 
stored at -20°C.  From the resuspended stock solution (0.2 µg/µL), 2 µL of working solution 
(200 pg/µL) was used in the electroporation procedures. 
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The commercially synthesized vectors were transformed into either E. coli MC1061 or E. 
coli Top10.  Transformants were plated on LB agar supplemented with the appropriate antibiotic, 
Em (150 µg/mL), Am (50 µg/mL), or Km (50 µg/mL).  Colony PCR was conducted to identify 
successful transformants.   
Purified plasmids pMJM-8, pMJM-13, and pMJM-14 were introduced into L. acidophilus 
NCFM, L. acidophilus ATCC 4356, L. crispatus CC1-1, L. crispatus JCM5810, L. gallinarum 
ATCC 33199, and L. helveticus CNRZ32 by electroporation.  Lactobacilli transformations were 
conducted as described by Luchansky, et al. (1988; Appendix C).  Briefly, lactobacilli cells were 
made electrocompetent using 3.5 × SMEB buffer (1 M sucrose and 3.5 mM magnesium chloride, 
pH 7) and electroporation was conducted at 2.5 kV using an Electroporator 2510 (Eppendorf, 
Westbury, NY, USA).  After 16 h incubation in MRS broth, the electroporated samples were 
spread plated on MRS agar supplemented with Em (5 µg/mL).  Large, cream-colored colonies 
grew within two days and were transferred three times in MRS broth containing Em (5 µg/mL).   
Recombinant Lactobacillus strains were confirmed through the plasmid isolation protocol 
(O’Sullivan and Klaenhammer, 1993; Appendix D) and subsequent PCR.  The PCR reaction 
conditions used are as follows.  The 50 µL reaction mixture began with an initial denaturation 
cycle of 94°C for 5 minutes; denaturation at 95°C for 30 seconds, annealing at 50°C for 1 
minute, elongation at 72°C for 2 minutes for 35 cycles; heated to 72°C for 10 minutes; and 
stored at 4°C (Biorad MyCycler
TM
, Hercules, CA).  The primers (pMJM13&14A and pMJM14R 
- BamHI) were designed using Clone Manager 9 (Sci-Ed Software) and were used to amplify a 
1,434 bp internal region of pMJM-13 and a 951 bp internal region of pMJM-14 (Table 3.3).  A 
series of forward primers were designed to amplify the internal region of pMJM-15 (Table 3.3).  
DNA fragments were purified from agarose gels using the Zymoclean Gel DNA Recovery Kit 
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(Zymo Research, Orange, CA) and submitted for sequencing at the UIUC Core Sequencing 
Facility (Urbana, IL).   
 
Protein Preparation and Western Blotting 
 
Protein expression of the successful transformants was evaluated using a Western Blot 
Assay.  Mid-log phase (OD600=0.5-0.8) cultures were harvested by centrifugation at room 
temperature, and sent for evaluation by collaborators at Washington State University.  Broth 
grown cultures were prepared in three manners, broth culture supernatant, sonicated supernatant, 
and resuspended pellet.  For the sonicated supernatant, the initial bacterial pellets were 
resuspended in PBS and sonicated for 10 min.  The resuspended pellet in PBS was recovered 
from the post-sonicated sample, due to difficulty in centrifuging the sample.  All three samples 
were mixed with 1× laemelli buffer and boiled 10 min (>95°C) before running the samples on 
polyacrylamide gels for blotting (Figure 3.9, Figure 3.10).  The protein sequence of C. jejuni flpA 
Domain II is predicted to have a size of 11 kD. 
 Supernatant of recombinant Lactobacillus strains in MRS (MJM272, MJM273, and 
MJM275) and MRS (negative control) was lyophilized to evaluate the presence of the secreted 
protein.  Overnight Lactobacillus cultures were passed into 100 mL of MRS and grown to 0.5 
OD600 nm.  Samples of 25 mL were aliquoted into 50 mL conical tubes and centrifuged at 3,200 × 
g at 4°C for 10 min.  The supernatant was transferred into a new 50 mL conical tube and the 
centrifugation steps repeated.  The final supernatant sample was lyophilized over 72 h in a 
vacuum freeze-dry system (Labconco, Kansas City, MO).  The sample was frozen at -20°C until 
further analysis.  The lyophilized sample was re-constituted in 1 mL PBS and centrifuged at 
3,220 × g at 4°C for 30 min.  The cell pellet and supernatant were then separated for analysis, 
50 
 
with the cell pellet re-suspended in 50 µL PBS.  The two samples were mixed with 1× laemelli 
buffer and boiled 10 min (>95°C) before analysis by SDS-Page (results not shown).   
 
Plasmid Construction Verification 
 
Β-glucuronidase (GUS) is widely used as a reporter gene to evaluate promoter activity 
and subsequent gene expression.  The Lactobacillus gasseri gusA is more active at acidic pH 
than its E. coli counterpart (Russell & Klaenhammer, 2001).  The mutant L. gasseri gusA3 
produces β-glucuronidase with increased activity in neutral pH ranges (Callanan et al., 2007).  
The L. gasseri β-glucuronidase (GusA3) reporter gene GenBank (AF305888) was synthesized 
(Genewiz, Inc.) and cloned via the XbaI/BamHI sites into the cloning vector pUC57 to construct 
pMJM-27 (Figure 3.11).  The vector pMJM-27 was transformed into E. coli MC1061 and the 
plasmid isolated from successful transformants plated on LB supplemented with Em (150 
µg/mL).   
The vectors pMJM-14 and pMJM-27 were enzyme digested at the XbaI/BamHI sites 
according to standard procedures.  The enzyme digested plasmids underwent gel electrophoresis 
and were excised from the agarose gel, followed by gel extraction and purification steps.  GusA3 
was cloned via the XbaI/BamHI sites into pMJM-14 to construct pMJM-28 (Figure 3.12) to 
evaluate expression of Ppgm.  As previously described, the vector (pMJM-28) was transformed 
into E. coli MC1061, grown overnight, and the plasmid isolated then sequence verified with 
primers GusA3_4681, GusA3_5052, GusA3_5470, and GusA3_5860 (Table 3.3).  The vector 
(pMJM-28) was transformed into Lactobacillus strains (MJM 7, MJM 39, MJM 207, and MJM 
208) and transformants were plated on MRS agar supplemented with Em (5 µg/mL) and 5-
Bromo-4-chloro-1H-indol-3-yl β-D-glucopyranosiduronic acid (X-gluc).  The blue colonies were 
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recovered and the plasmids isolated for sequence verification.  An overnight culture (50µL) was 
centrifuged for 5 min at 8,327 × g and reconstituted with PBS, then mixed with 1× laemelli 
buffer and boiled 10 min (>95°C) before running the samples on polyacrylamide gels for 
blotting.  The protein sequence of L. gasseri gusA3 is predicted to have a size of 70 kDa. 
 
Cell Wall Binding Domain 
 
To evaluate the cell wall binding of a heterologous protein to the surface of lactobacilli, 
additional cassettes were constructed that employ three cell wall binding domains (Figure 3.13).  
The cell wall binding domains selected include L. gasseri ATCC 33323 LysM domain-
containing protein (L. gasseri LysM; NCBI Ref. YP_814716.1); L. gasseri ATCC 33323 
Lysozyme M1, Bacterial SH3 domain (L. gasseri Lysozyme SH3; NCBI Ref. YP_814010.0); 
and L. lactis subsp. cremoris MG1363 AcmA protein (L. gasseri AcmA; GenBank 
CAL96887.1).  The L. gasseri LysM domain and L. gasseri Lysozyme SH3 domains were 
predicted in the literature (Kleerebezem et al., 2010) based on identification in the LocateP 
Database (www.cmbi.ru.nl/).  The L. lactis subsp. cremoris cell wall binding protein region of 
the AcmA protein was identified in separate literature (Raha et al., 2005).  Proteins of interest 
were then queried under the NCBI Conserved Domain Search and evaluated for gene product, 
family, and relevant description.   The sequences of the genes of interest (flpA DII and enhanced 
green fluorescent protein (EGFP)) and the cell wall binding domains (L. gasseri LysM, L. 
gasseri Lysozyme SH3, and L. lactis subsp. cremoris AcmA) were codon optimized based on the 
codon usage table of E. coli (www.idtdna.com/).   
The cassettes were synthesized as gBlocks
®
 Gene Fragments by IDT and cloned with 
blunt ends into pUC19 digested with SmaI.  This ligation formed the following plasmids, pMJM-
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30 (pUC19 with C. jejuni flpA DII), pMJM-31 (pUC19 with L. gasseri LysM), pMJM-32 
(pUC19 with L. gasseri Lysozyme SH3), and pMJM-33 (pUC19 with L. lactis subsp. cremoris 
AcmA) (Table 3.2).  Electrocompetent E. coli Top10 cells were transformed and successful 
transformants identified using blue-white screening of cells on LB agar supplemented with Am 
(50 µg/mL), 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal), and IPTG.  The 
isolated and purified plasmids were enzyme digested with the appropriate restriction enzymes 
then underwent gel electrophoresis and agarose gel purification.   
Enzyme digested samples underwent a three-piece ligation reaction including the cell 
wall binding domain cut via XhoI/HindIII, the C. jejuni FlpA cut via BamHI/XhoI, and the vector 
cut via BamHI/HindII (pRSET-B, Invitrogen, Carlsbad, CA, USA).  These ligation procedures 
constructed six vectors that contain either flpA DII or EGFP, with one of three cell wall binding 
domains (L. gasseri LysM, L. gasseri Lysozyme SH3, or L. lactis subsp. cremoris AcmA).  The 
vectors are represented schematically along with the expression cassette detailed for pMJM-37 
(Figure 3.14, Figure 3.15), pMJM-38 (Figure 3.16, Figure 3.17), pMJM-39 (Figure 3.18, Figure 
3.19), pMJM-40 (Figure 3.20, Figure 3.21), pMJM-41 (Figure 3.22, Figure 3.23), and pMJM-42 
(Figure 3.24, Figure 3.25).  Following transformation of electrocompetent E. coli BL21 (DE3) 
cells, successful transformants were selected on LB agar supplemented with ampicillin (50 
µg/mL) and the isolated plasmid then purified for sequence verification.   
The pRSET-B expression vector was chosen for high-level recombinant protein 
expression in E. coli.  Integral features of the vector include T7 promoter, ribosome binding site, 
N-terminal (6xHis) tag, T7 gene 10 sequence, N-terminal Xpress
TM
 epitope tag, enterokinase 
cleavage site, multiple cloning site, T7 reverse priming site, and an ampicillin resistance gene (β-
lactamase).  This cassette utilized the inducible T7 promoter to express the C. jejuni FlpA 
53 
 
Domain II.  Induction was achieved by the addition of isopropyl β-D-thiogalactoside (IPTG).  
The cassette contains a polyhistidine (6xHis) tag region and Xpress
TM
 epitope for ease of 
identification.  Several of the constructed plasmids are derivatives of pRSET-B (Table 3.2). 
The green fluorescent protein (GFP) serves as a tool for evaluation of protein expression.  
In particular, pEGFP-N1 contains a mutant of the wild-type GFP allowing for greater expression 
in mammalian cells and brighter red fluorescence (Invitrogen).  For verification, an additional 
cassette was created with EGFP and the three cell wall binding domains (Figure 3.13).  The 
primers LZ_EGFP F and LZ_EGFP R-XhoI (Table 3.3) were used to amplify a 719 bp internal 
region of pEGFP-N1.  The primers AB_FlpA F and AB_FlpA R (Table 3.3) were used to 
amplify a 295 bp internal region of pMJM-37, pMJM-38, and pMJM-39.  The primers 
pRSETB_F and pRSETB_R (Table 3.3) were used to amplify a 286 bp internal region of 
pRSETB.   
E. coli BL21 (DE3) containing pMJM-37 – pMJM-42 were evaluated for protein 
expression with a Western Blot Assay.  Culture samples were mixed with 1× laemelli buffer and 
boiled 10 min (>95°C) before running the samples on polyacrylamide gels for blotting.  The 
protein sequence of EGFP is predicted to have a size of 27.3 kDa.  The protein sequence of 
LysM is predicted to have a size of 7.2 kDa. The protein sequence of Lysozyme SH3 is predicted 
to have a size of 27.2 kDa.  The protein sequence of AcmA is predicted to have a size of 22.3 
kDa.   
 For purification of the recombinant protein fragment and binding to Lactobacillus spp., 
the cell culture was harvested 2-3 h following induction and resuspended in 1×PBS (Raha et al., 
2005).  The cells were then lysed and centrifuged at 10,000 × g for 15 min.  The supernatant was 
applied to a Ni
2+
 affinity column and the recombinant protein eluted to calculate the final 
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concentration.  Exponentially growing Lactobacillus spp. were centrifuged and resuspended in 
600 µl of MRS broth.  Then 200 µl of purified flpA DII was added to the cells and incubated at 
30°C for 2 h.  Following incubation, the mixture underwent centrifugation at 2,000 × g for 10 
min and washing of the cell pellet three times with 1 mL 1×PBS.  Binding of the purified protein 
and attached domains to Lactobacillus spp. was evaluated by ELISA and fluorescence 
microscopy.    
 
 
3.4 Results 
 
Previous research indicated the ability for L. acidophilus NCFM, L. crispatus JCM5810, 
and L. helveticus CNRZ32 to competitively exclude C. jejuni in the GIT of broiler chickens 
(Neal-McKinney et al., 2012).  Additionally, Lactobacillus spp. have been shown to impart 
beneficial effects which include the reduction of pathogenic colonization.  Lactobacilli produce 
organic acids and bacteriocins, modulate the host immune response, and manipulate the host 
microbiome.  Therefore, the four selected lactobacilli strains were chosen as host strains for 
recombinant protein expression.  
An important consideration when designing recombinant protein expression vectors is 
codon optimization.  This additional step advantageously alters the codons to those preferred by 
the targeted bacteria, while maintaining the amino acid sequence of the synthesized protein.  
Attention must be spent verifying the codon optimized sequence in order to confirm the presence 
of the correct amino acid sequence as well as restriction enzymes.  Unfortunately, the first 
synthesis of the cassette design was not properly verified before synthesis.  The restriction 
enzyme sites were found codon optimized out of the sequence.  Therefore, the plasmid was 
unable to be digested at the desired restriction enzyme sites and was deemed unusable.  
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Fortunately, Genewiz, Inc. was contacted willing to assist with resolving this error and the 
restriction enzyme sites were corrected and shipped following verification of sequence analysis.       
Re-growth of recombinant lactobacilli strains, particularly MJM270 and MJM271, from 
12.5% glycerol stock stored at -80°C was difficult at times.  Therefore, the Em concentration was 
reduced from 5 µg/mL to 2.5 µg/mL.  Previously 2.5 µg/mL Em was sufficient to prevent 
background growth of untransformed lactobacilli.  In order to confirm recombinant protein 
expression in vitro, a Western Blot Assay was performed.  The estimated molecular mass of the 
recombinant protein expressed on the cell surface is 11 kDa.   Unfortunately, the Western Blot 
Assay did not did not indicate the presence of the FlpA DII protein from all transformed 
lactobacilli grown in MRS broth supplemented with 2.5 µg/mL Er (Figure 3.9, Figure 3.10).  
While this protein has a low molecular weight (>15 kDa), it should still be able to be visualized 
using a Western Blot Assay.  Therefore, systemically each strain was tested for the presence of 
the Flpa DII cassette.  It was discovered that the L. crispatus strains (MJM 270 and MJM 271) 
found to be lacking the plasmids pMJM13 and pMJM14, respectively.  This explains the 
difficulty of the strains to grow in the Em conditions originally intended (5 µg/mL).  All other 
transformed lactobacilli strains that were confirmed to contain pMJM-13 and pMJM-14; 
however, it is not clear why the recombinant protein was not expressed or detected.  Additional 
steps were then taken to evaluate the plasmid construction and promoter expression.   
Supernatant of the recombinant Lactobacillus strains in MRS (MJM272, MJM273, and 
MJM275) and MRS (negative control) were lyophilized and resuspended in PBS to evaluate with 
SDS-Page.  Strains that contained pMJM-13 and pMJM-14 did not indicate expression of a 
protein in the predicted protein size.  This is not surprising, as secreted proteins are difficult to 
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express in media in sufficient concentrations for detection.  Additional steps will be taken to 
precipitate the protein following an acetone protocol.    
Further lactobacilli transformations had isolates present on MRS agar with Em (5 
µg/mL), yet plasmid isolation protocols and gel electrophoresis of PCR product did not indicate 
the presence of a plasmid.  The concentration of Em in the MRS agar plates was verified to 
select for only recombinant lactobacilli.  This approach was postponed until further evaluation of 
the plasmid construct.   
To evaluate the construction of the cassette, L. gasseri gusA3 was ligated via the 
XbaI/BamHI sites into pMJM-14.  Then pMJM-28 was transformed into E. coli MC1061 and an 
isolate was obtained.  Upon amplification of pMJM-28 in E. coli MC101, the plasmid was 
purified and remains to be transformed into Lactobacilli strains.  Expression of GusA3 by 
lactobacilli strains will indicate the functionality of the vector construction.  
 
 
3.5 Discussion 
 
In the poultry industry, strategies to reduce C. jejuni colonization in broiler chickens 
remain limited.  Lactobacillus spp. displaying heterologous proteins function as both a probiotic 
and as a vaccine for stimulation of the host GIT.  Anchoring of a foreign antigen to the cell wall 
produces a larger antigen response, than secreted or cytoplasmic protein expression (Bermudez-
Humaran et al., 2004, Norton et al., 1996).  A vector for C. jejuni FlpA DII protein expression 
anchored (pMJM-13) or secreted (pMJM-14) onto the wall of several Lactobacillus spp. was 
constructed.  Stimulation of the broiler chicken immune system prior to C. jejuni challenge 
would contribute to the reduction of pathogen colonization and incidence of human illness.    
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The cassette design was modeled after a successful dual cell surface display of HIV-1 
gag and Salmonella enterica serovar Typhimurium in Lactobacillus acidophilus NCFM intended 
for vaccine delivery (Kajikawa et al., 2012).  Production of the Gag protein was confirmed by 
Western Blotting.  BALB/c mice were immunized intragastrically with the recombinant 
Lactobacillus strains.  Following collection of lymphoid tissues and organs for detection of IgA-
producing cells, it was demonstrated that induction of Gag-specific IgA-producing cells was 
present at the local intestinal mucosa.  Only recombinant bacterial strains displaying Gag and 
FliC elicited this immune response, as recombinant strains displaying Gag only did not promote 
this effect.  Based on the success of the in vitro and in vivo experiments with the dual display of 
Gag and FliC, we constructed a similar cassette that displayed C. jejuni FlpA Domain II rather 
than HIV-1 Gag.  Electing to exclude the FliC adjuvant, we focused on the expression of FlpA.  
Even without the FliC adjuvant present, the authors were able to confirm production of the Gag 
protein by Western Blotting.  However, our similarly modeled construct was unable to express 
FlpA by Western Blotting.  Whether due to error in the sequence or a frameshift mutation, this 
issue has not yet been fully resolved. 
To evaluate the cassette construct, gusA3 was ligated into pMJM14 and remains to be 
transformed into Lactobacillus strains and evaluated for protein production by Western Blotting.  
The GusA3 reporter gene was previously cloned for characterization of operons implicated in 
transport and catabolism of fructooligosaccharides (FOS), lactose (lac), trehalose (tre) and genes 
directing glycosis (Duong et al., 2011).  The construct based on phosphoglycerate mutase (pgm) 
promoter was constitutively highly expressed.  Thus, Ppgm has previously expressed GusA3 in 
Lactobacillus. 
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The strategy of recombinant Lactobacillus expressing FlpA through either secreted or 
anchored mechanisms was suspended in favor of attaching FlpA to Lactobacillus through 
various cell wall binding domains.  While still in its infancy, the use of non-genetically modified 
organisms has great potential for use in the food industry.  First, these strains cannot propagate 
the protein into subsequent generations, thus limiting concerns of horizontal gene transfer.  
Second, the attachment to the cell surface ensures the protein is present upon delivery, rather 
than assuming the protein is expressed while in the GIT.  However, there are limitations as in 
vivo models remain limited and there exist concerns of structural degradation. 
For the future, additional approaches include evaluation of the promoter strength.  For 
recombinant bacterial cells, it’s imperative that a balance exists between basal metabolic 
functions and expression of the foreign antigen.  In the case of anchoring proteins, too strong of a 
promoter may result in cell surface attachment of foreign antigens that inhibit the functionality of 
basic cell processes.  In turn, the cell cannot balance environmental stresses with protein 
expression and may lyse.  Selection of the appropriate promoter strength maintains this delicate 
balance.  While Ppgm has been noted as one of the strongest promoters in Lactobacillus, 
alternative promoters may be considered to limit protein expression.  Inducible promoters offer 
more flexibility for protein expression because they must be activated by either chemical or 
physical factors for protein expression to occur.  Therefore, the selected lactobacilli strains may 
benefit from an inducible promoter over a constitutive promoter. 
This project outlines two different mechanisms as an alternative strategy to current 
methods targeting the reduction of C. jejuni colonization in broiler chickens.  The first includes 
the proven stimulation of GI host immune responses through exposure to probiotics (Avall-
Jaaskelainen & Palva, 2005, Bernardeau et al., 2008, Borchers et al., 2009).  The second focuses 
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on the cell wall binding of foreign antigens to the exterior surface of Lactobacillus cells to elicit 
a specific immune response.  In both cases, the clear aim is to target and to stimulate host 
receptors for prevention of C. jejuni colonization.  A mucosal live vaccine in mice utilized L. 
casei and Lactococcus lactis displayed E7 antigen (cell-binding domain from L. casei A2 phage 
lysine) as the cell wall anchor (Ribelles et al., 2013).  This non-genetically modified lactic acid 
bacteria was vaccinated intranasally in mice and prevented HPV-16-induced tumor formation.  
We propose the novel approach of inoculating non-genetically modified lactobacilli strains 
displaying the C. jejuni FlpA DII protein for the express purpose to reduce C. jejuni colonization 
in broiler chickens. 
 
 
3.6 Conclusion 
 
While other researchers have successfully secreted and anchored foreign antigens on the 
surface of lactobacilli, we were unable to isolate and to verify successful transformants in this 
study.  Additional work will be conducted to evaluate the plasmid construction and component 
sequences.  For the future, we propose a non-genetically modified lactic acid bacteria for 
vaccination and reduction of C. jejuni colonization of broiler chickens.  Upon optimization of 
this strategy, conducting in vivo experimental procedures will evaluate the efficacy of 
Lactobacillus strains as vaccine vectors.    
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3.8 Tables and Figures 
 
Table 3.1 List of bacterial strains 
Strain or plasmid Relevant Characteristics Source or reference 
Lactobacillus     
MJM7 L. acidophilus NCFM Klaenhammer Lab 
MJM39 L. acidophilus ATCC 4356 NCAUR 
MJM114 L. acidophilus ATCC 4356 (pMJM-8) This study 
MJM206 L. crispatus CC1-1 Konkel Lab 
MJM207 L. crispatus JCM5810 Konkel Lab 
MJM208 L. gallinarum ATCC 33199 Konkel Lab 
MJM209 L. helveticus CNRZ32 Konkel Lab 
MJM270 L. crispatus CC1-1 (pMJM-13) This study 
MJM271 L. crispatus CC1-1 (pMJM-14) This study 
MJM272 L. gallinarum ATCC 33199 (pMJM-13) This study 
MJM273 L. gallinarum ATCC 33199 (pMJM-14) This study 
MJM274 L. crispatus CC1-1 (pMJM-8) This study 
MJM275 L. gallinarum ATCC 33199 (pMJM-8) This study 
MJM322 L. acidophilus ATCC 4356 (pMJM-14) This study 
MJM330 L. acidophilus NCFM (pMJM-8) This study 
MJM332 L. acidophilus NCFM (pMJM-14) This study 
   Escherichia coli     
NCK 87 E. coli MC1061 Klaenhammer Lab 
MJM106 E. coli MC1061 (pMJM-8) Miller Lab 
MJM256 E. coli MC1061 (pMJM-13) This study 
MJM257 E. coli MC1061 (pMJM-14) This study 
MJM258 E. coli MC1061 (pMJM-15) This study 
MJM329 E. coli MC1061 (pMJM-27) This study 
MJM333 E. coli MC1061 (pMJM-28) This study 
MJM335* E. coli Top10 (pMJM-30) This study 
MJM336* E. coli Top10 (pMJM-31) This study 
MJM337* E. coli Top10 (pMJM-32) This study 
MJM338* E. coli Top10 (pMJM-33) This study 
MJM342* E. coli BL21 (DE3) (pMJM-37) This study 
MJM343* E. coli BL21 (DE3) (pMJM-38) This study 
MJM344* E. coli BL21 (DE3) (pMJM-39) This study 
MJM345* E. coli BL21 (DE3) (pMJM-40) This study 
MJM346* E. coli BL21 (DE3) (pMJM-41) This study 
MJM347* E. coli BL21 (DE3) (pMJM-42) This study 
MJM348* E. coli MC1061 (pUC19) This study 
MJM349* E. coli MC1061 (pEGFP-N1) This study 
* In progress, remains to be constructed. 
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Table 3.2 List of plasmids  
 
Plasmids     
pMJM-8 Em
R
, E. coli and Lactobaciluus Shuttle Vector Miller Lab 
pMJM-13 Em
R
, derivative of pMJM-8, Secreted and anchored 
C. jejuni flpA DII, PGM promoter 
This study 
pMJM-14 Em
R
, derivative of pMJM-8, Secreted C. jejuni flpA 
DII, A1392 anchor signal deleted , PGM promoter 
This study 
pMJM-15 Em
R
, derivative of pMJM-8, S. enterica serovar 
Typhimurium 
This study 
pMJM-27 Ap
R
, gusA3 in pUC57 This study 
pMJM-28 Ap
R
, gusA3 in pMJM14 This study 
pMJM-30* Ap
R
, pUC19 with blunt-end ligation of C. jejuni flpA 
DII Insert 
This study 
pMJM-31* Ap
R
, pUC19 with blunt-end ligation of L. gasseri 
LysM 
This study 
pMJM-32* Ap
R
, pUC19 with blunt-end ligation of L. gasseri  
Lysozyme, SH3 domain 
This study 
pMJM-33* Ap
R
, pUC19 with blunt-end ligation of L. lactis 
subsp. cremoris AcmA 
This study 
pMJM-37* Ap
R
, pRSET-B with ligation of C. jejuni flpA DII and 
L. gasseri LysM 
This study 
pMJM-38* Ap
R
, pRSET-B with ligation of C. jejuni flpA DII and 
Lysozyme SH3 
This study 
pMJM-39* Ap
R
, pRSET-B with ligation of C. jejuni flpA DII and 
AcmA 
This study 
pMJM-40* Ap
R
, pRSET-B with ligation of EGFP and L. gasseri 
LysM 
This study 
pMJM-41* Ap
R
, pRSET-B with ligation of EGFP and Lysozyme 
SH3 
This study 
pMJM-42* Ap
R
, pRSET-B with ligation of EGFP and AcmA This study 
pUC19 Ap
R
, cloning vector Invitrogen 
pRSET-B Ap
R
, expression vector BD Biosciences 
pEGFP-N1 Km
R
, encodes the GFPmut1 variant BD Biosciences 
* In progress, remains to be constructed. 
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Table 3.3 Primer sequences for plasmid gene amplification  
 
Gene product Primers (Orientation) Sequence (5’→ 3’) 
pMJM-13, 
pMJM-14 –
Insert 
LZ_pMJM13&14A (F) TTTTGATGGTGTATCTAAAACATT 
pMJM13&14B (F) GGTTCAATTTTCTTCTGGACAAAC 
AB_p14R_BamHI (R) TCGAAATTAACCCTCACTAAAG 
pMJM-15 – 
fliC insert 
AB_pMJM15A (F) GGTATTTGGACTCCTGTAAAGAAT 
AB_pMJM15B (F) TATCGAGCGTTTGAGTTCAGGTTT 
AB_pMJM15C (F) CAATTGCTTTAGACAACAGTACAT 
AB_pMJM15D (F) AACAAGTTAGGTGGAGCAGACGGT 
AB_pMJM15E (F) AACACCACAACCAGAGCCAAACCC 
GusA3 GusA3_4681 (F) CTTCTTTATTCCTTCATTTC 
GusA3_5052 (F) ATAAGGCAACAATTACCTAC 
GusA3_ 5470 (F) CGAAGAATGGTATCAATATG 
GusA3_ 5860 (R)  CTGCTTAAACCGTTATTATG 
FlpA AB_FlpA F (F) GGATCCGATGCGCTTGGAGG 
AB_FlpA R (R) CTCGAGAGTAGACGACACAACTTGAGATGA 
EGFP LZ_EGFP F (F) CGCGGATCCGATGGTGAGCAAGGG 
LZ_EGFP R-Xhol (R) CCGCTCGAGCTTGTACAGCTCGT 
pRSET-B 
insert 
pRSETB_F (F) TAATACGACTCACTATAGGG 
pRSETB_R (R) CTAGTTATTGCTCAGCGGTGG 
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Figure 3.1 Schematic of plasmid pMJM-8. Multi-cloning site indicated by cluster of restriction 
enzyme sites. 
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Figure 3.2. Gene map of an expression cassette for C. jejuni flpA and S. enterica serovar 
Typhimurium fliC. Figure A indicates cassette in pMJM-13, Figure B indicates cassette in 
pMJM-14, and Figure C indicates cassette in pMJM-15.  Ppgm, promoter region of pgm gene 
from L. acidophilus NCFM; R, region encoding ribosome binding site of Mub from L. 
acidophilus NCFM (LBA1709 or LBA1392); S1709/S1392, region encoding the signal sequence of 
Mub (LBA1709 or LBA 1392); flpA, flpA gene from C. jejuni; A1709/A1392, region encoding the 
anchor region of Mub (LBA1709 or LBA 1392); fliC, fliC gene from S. enterica serovar 
Typhimurium.  
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Figure 3.3 Schematic of plasmid pMJM-13.  Secreted and anchored C. jejuni FlpA DII.  Insert 
represented as ORF-1. 
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Figure 3.4 Sequence of expression cassette in pMJM-13.  Ppgm, promoter region of pgm gene 
from L. acidophilus NCFM; RBS, region encoding ribosome binding site of Mub from L. 
acidophilus NCFM (LBA1709); S1709, region encoding the signal sequence of Mub (LBA1709); 
flpA DII, flpA gene from C. jejuni, domain II; A1392, region encoding the anchor region of Mub 
(LBA 1392).  Restriction sites are underlined.   
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Figure 3.5 Schematic of plasmid pMJM-14.  Secreted C. jejuni FlpA DII.  Insert represented as 
ORF-1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pMJM-14
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Figure 3.6 Sequence of expression cassette in pMJM-14.  Ppgm, promoter region of pgm gene 
from L. acidophilus NCFM; RBS, region encoding ribosome binding site of Mub from L. 
acidophilus NCFM (LBA1709); S1709, region encoding the signal sequence of Mub (LBA1709); 
flpA DII, flpA gene from C. jejuni, domain II.  Restriction sites are underlined.   
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Figure 3.7 Schematic of plasmid pMJM-15.  fliC gene from Salmonella enterica serovar 
Typhimurium.  Insert represented as ORF-1. 
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Figure 3.8 Sequence of expression cassette in pMJM-15.  RBS, region encoding ribosome 
binding site of Mub from L. acidophilus NCFM (LBA1392); S1392, region encoding the signal 
sequence of Mub (LBA 1392); fliC, fliC gene from S. enterica serovar Typhimurium; A1709, 
region encoding the anchor region of Mub (LBA1709).  Restriction sites are underlined.   
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Figure 3.8 Continued. 
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Figure 3.9 Protein Verification of C. jejuni FlpA DII.  Figure A indicates samples from the 
sonication supernatant.  Figure B indicates sonicated cell pellet resuspended in PBS. Samples are 
as follows (1) Campylobacter whole cell lysate (WCL) 1:1000, (2) L. crispatus MJM206, (3) L. 
crispatus MJM270, (4) L. crispatus MJM271, (5) L. gallinarum MJM208, (6) L. gallinarum 
MJM272, (7) L. gallinarum MJM273, (8) Blank, and (9) Campylobacter WCL 1:1000.  
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Figure 3.10 Protein Verification of C. jejuni FlpA DII. Samples are as follows (1) L. acidophilus 
ATCC 4356 (MJM 114), (2) L. gallinarum ATCC 33199 (MJM 272), (3) L. gallinarum ATCC 
33199 (MJM 273), (4) L. gallinarum ATCC 33199 (MJM 275), (5) L. acidophilus NCFM 
(MJM330), (6) L. acidophilus ATCC 4356 (MJM322), (7) L. acidophilus NCFM (MJM332), and 
(8) Campylobacter WCL 1:1000. 
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Figure 3.11 Schematic of plasmid pMJM-27. Derivative of pUC57 with L. gasseri GusA3 
(Callanan et al., 2007).  Insert represented as ORF-1. 
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Figure 3.12 Schematic of plasmid pMJM-28.  Derivative of pMJM-14 with L. gasseri GusA3 
(Callanan et al., 2007).  Insert represented as ORF-1. 
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Figure 3.13 Gene map of an expression cassette for cell wall binding domains and genes of 
interest ligated into pRSET-B.  Figure A indicates the cassette with C. jejuni flpA Domain II and 
Figure B indicates the cassette with EGFP sequenced from pEGFP-N1 (GenBank U55762).  PT7, 
promoter region of the T7 bacteriophage; R, region encoding ribosome binding site; ATG, 
translational initiation site for fusion protein; N-terminal 6xHis tag, allows for purification of 
fusion protein on metal-chelating resins and allows for antibody detection of fusion protein; N-
terminal Xpress
TM
 epitope tag, allows detection of fusion protein by the Xpress
TM
 antibody; EK, 
enterokinase cleavage site to remove fusion tag; flpA, flpA gene from C. jejuni; EGFP, enhanced 
β-glucuronidase from pEGFP-N1; Cell wall BD, cell wall binding domains on C-terminal. 
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Figure 3.14 Schematic of plasmid pMJM-37.  Derivative of pRSET-B with flpA, flpA gene from 
C. jejuni; LysM, LysM domain from L. gasseri.  Insert represented as ORF-1. 
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Figure 3.15 Sequence of expression cassette in pMJM-37.  Features found in pRSET-B (T7 
promoter, RBS (Ribosome binding site), N-terminal Polyhistidine (6xHis) region, T7 gene 10 
leader, N-terminal Xpress
TM
 Epitope, EK recognition site (Enterokinase cleavage site), T7 
reverse priming site; flpA, flpA gene from C. jejuni; LysM, LysM domain from L. gasseri.  
Restriction sites are underlined.   
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Figure 3.16 Schematic of plasmid pMJM-38.  Derivative of pRSET-B with flpA gene from C. 
jejuni; Lysozyme SH3 domain from L. gasseri (LGAS0160).  Insert represented as ORF-1. 
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Figure 3.17 Sequence of expression cassette in pMJM-38.  Features found in pRSET-B (T7 
promoter, RBS (Ribosome binding site), N-terminal Polyhistidine (6xHis) region, T7 gene 10 
leader, N-terminal Xpress
TM
 Epitope, EK recognition site (Enterokinase cleavage site), T7 
reverse priming site; flpA, flpA gene from C. jejuni; SH3, Lysozyme SH3 domain from L. gasseri 
(LGAS0160).  Restriction sites are underlined.   
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Figure 3.17 Continued. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
85 
 
Figure 3.18 Schematic of plasmid pMJM-39.  Derivative of pRSET-B with flpA gene from C. 
jejuni; AcmA domain from L. lactis subsp. cremoris.  Insert represented as ORF-1. 
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Figure 3.19 Sequence of expression cassette in pMJM-39.  Features found in pRSET-B (T7 
promoter, RBS (Ribosome binding site), N-terminal Polyhistidine (6xHis) region, T7 gene 10 
leader, N-terminal Xpress
TM
 Epitope, EK recognition site (Enterokinase cleavage site), T7 
reverse priming site; flpA, flpA gene from C. jejuni; AcmA, AcmA domain from L. lactis subsp. 
cremoris.  Restriction sites are underlined.   
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Figure 3.20 Schematic of plasmid pMJM-40.  Derivative of pRSET-B with EGFP gene from 
pEGFP-N1; LysM domain from L. gasseri.  Insert represented as ORF-1. 
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Figure 3.21 Sequence of expression cassette in pMJM-40.  Features found in pRSET-B (T7 
promoter, RBS (Ribosome binding site), N-terminal Polyhistidine (6xHis) region, T7 gene 10 
leader, N-terminal Xpress
TM
 Epitope, EK recognition site (Enterokinase cleavage site), T7 
reverse priming site; EGFP, EGFP gene from pEGFP-N1; LysM, LysM domain from L. gasseri.  
Restriction sites are underlined.   
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Figure 3.22 Schematic of plasmid pMJM-41.  Derivative of pRSET-B with EGFP gene from 
pEGFP-N1; Lysozyme SH3 domain from L. gasseri (LGAS0160).  Insert represented as ORF-1. 
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Figure 3.23 Sequence of expression cassette in pMJM-41.  Features found in pRSET-B (T7 
promoter, RBS (Ribosome binding site), N-terminal Polyhistidine (6xHis) region, T7 gene 10 
leader, N-terminal Xpress
TM
 Epitope, EK recognition site (Enterokinase cleavage site), T7 
reverse priming site; EGFP, EGFP gene from pEGFP-N1; SH3, Lysozyme SH3 domain from L. 
gasseri (LGAS0160).  Restriction sites are underlined.   
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Figure 3.23 Continued. 
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Figure 3.24 Schematic of plasmid pMJM-42.  Derivative of pRSET-B with EGFP gene from 
pEGFP-N1; AcmA domain from L. lactis subsp. cremoris.  Insert represented as ORF-1. 
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Figure 3.25 Sequence of expression cassette in pMJM-42.  Features found in pRSET-B (T7 
promoter, RBS (Ribosome binding site), N-terminal Polyhistidine (6xHis) region, T7 gene 10 
leader, N-terminal Xpress
TM
 Epitope, EK recognition site (Enterokinase cleavage site), T7 
reverse priming site; EGFP, EGFP gene from pEGFP-N1; AcmA, AcmA domain from L. lactis 
subsp. cremoris.  Restriction sites are underlined.   
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Figure 3.25 Continued. 
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CHAPTER 4 CAMPYLOBACTER COLONIZATION OF BROILER CHICKENS 
 
 
 
4.1 Abstract 
 
Campylobacter spp. are commensal, zoonotic bacteria that colonize the gastrointestinal 
tract of broiler chickens.  Additionally, Campylobacter jejuni is a leading foodborne pathogen 
that causes the human illness, campylobacteriosis, characterized by diarrhea, abdominal pain, 
cramping, and in rare cases Guillain-Barré Syndrome.  Human exposure to C. jejuni occurs 
primarily via cross-contamination and inadequate heating of retail chicken meat.  C. jejuni is 
estimated to contaminate over 60% of retail poultry meat.  Targeted reduction of C. jejuni on the 
poultry farm could lessen the risk of consumer exposure to C. jejuni from retail poultry meat.  
The goal of this study was to develop a model for C. jejuni colonization of broiler chickens, to 
utilize for future treatment strategies.  Day-old broiler chickens were co-housed in stainless steel 
batteries and fed standard diet without bacitracin for three weeks.  On day 14, chickens (n=15 per 
treatment group) were orally administered with 10
9
 CFU/mL of either C. jejuni NCTC 11168, 
F38011, or PBS sham inoculum.  Chickens were euthanized and necropsied on d 21 for direct-
plating of the cecal contents on Mueller-Hinton blood agar and subsequent enumeration of C. 
jejuni.  While unsuccessful in the first study, the second study indicated the capability of C. 
jejuni to replicate and colonize the broiler chicken cecal crypts.  Critical components for 
colonization include handling of the inoculum to ensure the presence of flagella for chemotaxis 
and motility purposes.  Future studies may utilize this C. jejuni challenge model to impart 
treatment strategies. 
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4.2 Introduction  
 
Campylobacter spp. are characterized as microaerophilic, non-spore-forming, Gram-
negative, with either a curved, S-shaped, or spiral rod.  Campylobacter is native to the 
gastrointestinal tract (GIT) of a wide range of animals. The zoonotic pathogen Campylobacter 
jejuni is the most researched member species of the genus Campylobacter.  C. jejuni easily 
colonizes broiler chickens as a commensal organism and serves as the primary source of C. 
jejuni for human infections.  In humans, C. jejuni infection results in campylobacteriosis, an 
acute gastroenteritis that causes an estimated 845,000 illnesses annually in the United States 
(Batz et al., 2011).  Campylobacter spp. have been identified as the third leading foodborne 
pathogen in annual burden of disease, including data from cost of illness and the number of 
illnesses, hospitalizations, and deaths  (Batz et al., 2011).  Therefore, developing novel strategies 
for the control of C. jejuni in broiler chickens is of great public interest.  
Interestingly, broiler chickens are protected from C. jejuni colonization early in life due 
to the presence of maternal antibodies.  However, maternal antibodies slowly diminish after three 
weeks and no longer protect the broiler chicks from colonization of the GIT by C. jejuni 
(Cawthraw & Newell, 2010, Sahin et al., 2003).  C. jejuni exploit a number of survival and 
colonization mechanisms to adapt to the ever-changing conditions of the chicken GIT (Hermans 
et al., 2011a).  Most importantly, the C. jejuni flagellum propels the organism through the GIT, 
overcomes host protective mechanisms, and promotes internalization into the deep cecal crypts.  
Mutant strains lacking formation of a functional flagellum exhibit dramatically decreased levels 
of internalization (Grant et al., 1993).   Multiple animal studies have demonstrated the necessity 
of C. jejuni motility and chemotaxis for effective colonization (Chang & Miller, 2006, Morooka 
et al., 1985, Nachamkin et al., 1993).  The highest concentration of C. jejuni in broiler chickens 
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are found within the mucosal layer of the cecal crypts (between 10
6
 and 10
8
 colony-forming units 
(CFU)/g of cecal contents) (Allen et al., 2008, Beery et al., 1988, Hermans et al., 2012, Meade et 
al., 2009).  Following colonization of C. jejuni in the broiler chicken cecum, broiler chickens 
shed the bacterium in feces, resulting in colonization of the entire flock within a few days.  
Interestingly, C. jejuni is a commensal organism in chickens and colonization is not marked by 
observable clinical symptoms of infection (Newell & Fearnley, 2003).   
C. jejuni is commonly transmitted to humans via contamination of retail poultry meat.  
Spread of the bacterium often occurs during the defeathering and evisceration steps, as the 
carcasses are readily contaminated by fecal material (Hermans et al., 2011b).  Over 60% of retail 
poultry products test positively for the presence of Campylobacter (Nannapaneni et al., 2005, 
Wong et al., 2007, Zhao et al., 2001).  As a leading foodborne pathogen in the United States, C. 
jejuni in retail poultry meat products results in a $1.3 billion annual cost of illness (Batz et al., 
2011).  In humans, campylobacteriosis results in undesirable abdominal pain, cramping, diarrhea, 
and in rare circumstances Guillain-Barré Syndrome (GBS).  At the poultry farm, strategies for 
the reduction of C. jejuni colonization in broiler chickens remain underdeveloped. 
Prior to implementation of treatment strategies to reduce C. jejuni colonization, the 
laboratory must successfully colonize broiler chickens with C. jejuni.  Strain-to-strain variations 
are present amongst C. jejuni, with human isolates less likely to colonize chickens than poultry 
isolates (Korolik et al., 1998, Ringoir & Korolik, 2003).  Additionally, broiler chickens must be 
orally gavaged with a higher inoculum of C. jejuni (10
4
-10
6
 CFU/mL), as compared to cloacal 
challenge (<10
2
-10
4
 CFU/mL) (Shanker et al., 1988).  Previous research studies have 
successfully colonized the chicken GIT following oral inoculation (Beery et al., 1988, Konkel et 
al., 2007, Line et al., 2008, Van Deun et al., 2008).  Therefore, our objective was to develop lab 
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specific protocols and procedures for the colonization of broiler chickens with C. jejuni and the 
recovery of C. jejuni from the cecal crypts.   
 
4.3 Materials and Methods 
 
Bacterial Strains and Growth Conditions 
Campylobacter jejuni NCTC 11168 and F38011 (kindly provided by Dr. Michael 
Konkel, Washington State University, Pullman, Washington) were grown on Mueller-Hinton 
(Difco) broth supplemented with 1.5% agar (Fisher) and 5% bovine citrate blood (Quad Five, 
Ryegate, MT; MH blood agar) (Figure 4.1).  Microaerobic growth occurred in a VWR incubator 
(Radnor, PA) maintained at 37°C with a gas composition of 85% nitrogen, 10% carbon dioxide, 
and 5% oxygen.  Glycerol stock (stored at -80°C) of Campylobacter was streaked on MH blood 
agar and passed every 24-48 h before use as a primary culture.   
 
Broiler Chickens  
Day-old chickens were randomly divided into study groups and placed into cohabitated 
stainless steel batteries.  Broiler chickens inoculated with C. jejuni were housed separately from 
control broilers, with an established workflow to reduce risk of cross-contamination.  Water and 
standard diet without bacitracin were provided ad libitum.  Corn and soybean meal was procured 
from the University of Illinois Poultry Farm, which has previously used this feed for the 
upbringing of broiler chickens and layer hens.  Fecal material was collected in a removable metal 
tray below the wire mesh floor of the cage.  The studies were conducted at the University of 
Illinois with experiments and procedures approved by the University of Illinois Institutional 
Animal Care and Use Committee (IACUC; protocol no. 13059).   
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Study One – Campylobacter jejuni Colonization and 2’FL Treatment of Broiler Chickens 
This study sought to colonize Ross 708 broiler chickens with C. jejuni and to evaluate 2’-
Fucosyllactose (2’FL) as a treatment for reduction of C. jejuni colonization.  Broiler chicks were 
randomly assigned a treatment group.  The six treatment groups consisted of a (1) control group, 
C. jejuni free and no 2’FL, (2) C. jejuni challenged with no 2’FL dosage, (3) C. jejuni challenged 
with low 2’FL dosage (1 mg), (4) C. jejuni challenged with medium 2’FL dosage (10 mg), (5) C. 
jejuni free with high 2’FL dosage (100 mg), and (6) C. jejuni challenged with high 2’FL dosage 
(100 mg).  Each treatment group was assigned three cages of birds, which each held five birds, 
for a total of fifteen birds within each treatment group (Table 4.3).  With the exception of Group 
1 which had four cages of birds for twenty total birds and Group 5 which had two cages of birds 
for ten total birds.   
 
Inoculation of Campylobacter jejuni.  At 14 days of age, broiler chickens were inoculated with 
C. jejuni NCTC 11168 via oral gavage of a 0.2 mL bacterial suspension (~10
9
 CFU/mL).  The 
bacterial suspension was prepared as follows; a frozen stock was passed twice on MH blood agar 
at 37°C under microaerobic conditions.  Phosphate Buffered Saline (PBS) was added to the MH 
blood agar and a sterile loop was utilized to bring the colonies into suspension.  Inoculum was 
normalized by measuring the optical density at 600 nm wavelength (OD600 nm, Spec 21, Bausch 
and Lomb).  To confirm inoculum concentration, serial dilutions (10
3
-10
8
 CFU/mL) were made 
before plating on MH blood agar.  Plates were incubated as previously described and colonies 
were enumerated to determine the concentration of the inoculum.  All bacterial enumerations 
were performed in duplicate.  Control birds received PBS without C. jejuni, on the same dosage 
timeline. 
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Preparation of 2’FL.  The 2’FL was synthesized as previously described (Lee et al., 2012).  
Lyophilized 2’FL samples were solubilized in sterile PBS to final concentrations of 200, 20, and 
2 mg/mL to dose birds with 0.5 mL of 100, 10, and 1 mg, respectively.  For treatment groups 
receiving 2’FL, broiler chickens were orally gavaged with 2’FL suspended in PBS on days 19 
and 20 of age.  Control birds received PBS without 2’FL, on the same dosage timeline. 
 
Broiler Chicken Sampling Procedures.  At 21 days of age, all broiler chickens were removed 
from their batteries, weighed, and euthanized by carbon dioxide asphyxiation.  Ceca were 
removed following an incision made below the ribcage.  Cecal contents were collected 
aseptically and immediately prepared for enumeration of bacterial populations (as described 
below).  Cecal contents (~200 mg) for analysis by quantitative PCR (qPCR) were flash frozen in 
liquid nitrogen and stored at -80°C until use.  The handling of deceased experimental animals 
complied with University of Illinois IACUC and Division of Animal Resources welfare laws and 
guidelines.  Necropsy followed a tiered order of selecting one cage from each treatment group at 
a time, to account for potential Campylobacter oxygen sensitivities.  
 
Enumeration of Cecal Campylobacter Populations.  Both ceca were cut open longitudinally, 
weighed, diluted 1:2 (wt/vol) in Mueller Hinton Broth, and stomached for two min on high.  For 
enumeration, the stomached sample was diluted at 1:5 (wt/vol) in PBS followed by 10-fold serial 
dilutions.  Upon brief vortexing of samples, 10 µL from dilutions 10
-1
 to 10
-6
 was spread plated 
on Campy-Cefex agar plates (Appendix E).  The plates were incubated microaerobically (10% 
CO2, 5% O2) at 37°C for 72 h and colonies were counted and recorded.  All bacterial 
enumerations were performed in duplicate.  Contaminating growth was evident on lower 
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dilutions (10
3
 CFU/mL), with C. jejuni colonies (round, with orange- or salmon-colored 
colonies) observable on higher dilutions.  
 
DNA Extraction and Quantitative Real-Time PCR (qPCR).  DNA was extracted from flash-
frozen cecal content samples following established procedures (Barry et al., 2009, Yu & 
Morrison, 2004).  Step-by-step directions may be found in Appendix F.  The two aliquots were 
combined into one tube and 40 µL of DNase-free RNase added.  The samples were briefly 
vortexed and incubated at 37°C for 15 min.  DNA was purified using a QIAGEN Stool Mini Kit 
(Qiagen, Valencia, CA) with a modified protocol.  Briefly, 15 µL proteinase K were pipetted into 
the sample, according to the manufacturer’s instructions.  A positive control of C. jejuni NCTC 
11168 was used as an extraction control with each assay.  Samples were stored at -20°C until 
further use. 
A standard curve was prepared from extracted DNA of pure cultures of C. jejuni NCTC 
11168 grown overnight, following the procedures previously described.  The pure culture was 
normalized by optical density (OD600 nm) and DNA concentration measured (NanoDrop
TM
 1000 
Spectrophotometer, Thermo Scientific).  Serial dilutions (10
1
-10
9
 CFU/mL) were performed to 
create the Campylobacter standard curve. 
The internal control template was created from a set of primers specific for the 16S rRNA 
of Campylobacter (Bui et al., 2012) and purchased from Integrated DNA Technology 
(Coralville, IA).  The set of primers includes AB_Cjej1F (5’ – GCGTAGGCGGATTATCAAGT 
- 3’) and AB_Cjej1R (5’ – CGGATTTTACCCCTACACCA - 3’).  Two microliters of extracted 
bacterial DNA were added to 8 µl of reaction mixture (5 µl of 2X Power SYBR Green PCF 
Master mix (Applied Biosystems, Carlsbad, CA), bovine serum albumin at a final concentration 
102 
 
of 1 µg BSA/µL (New England Bio Labs), 0.5 µM of each primer).  The 10 µL qPCR reaction 
was quantified using the Applied Biosystems 7900HT Fast Real-Time PCR System (Applied 
Biosystems).  The amplification followed an initial denaturation cycle of 50°C for 2 min, 95°C 
for 10 min, followed by 40 cycles of 95°C for 15 s, and 60°C for 1 min.  Following 
amplification, a dissociation step was included to analyze the melting profile of the amplified 
products.  Data was analyzed using the SDS Standard Core 2.4.1 software package (Applied 
Biosystems) and samples were identified as either positive or negative for C. jejuni in 
comparison with the standard curve.  Positive and negative controls were included in each assay 
to confirm the limit of detection. 
 
Study Two – Campylobacter jejuni Colonization of Broiler Chickens 
The primary objective of this study was to colonize Ross 308 broiler chickens with C. 
jejuni and to verify the presence of C. jejuni in inoculated broiler chickens.  The study consisted 
of four randomly assigned groups, including (1) control group, C. jejuni free, (2) C. jejuni NCTC 
11168 challenged on day ten, (3) C. jejuni NCTC 11168 challenged on day fourteen, and (4) C. 
jejuni F38011 challenged on day fourteen.  Each treatment group was assigned three cages of 
birds, which each held five birds, for a total of fifteen birds within each treatment group (Table 
4.4).  If not receiving an inoculation, the birds received a control dose of PBS on day 10 and day 
14.  Necropsy of all birds occurred on day 21 of age. 
 
Inoculation of Campylobacter jejuni.  Care was taken when passing C. jejuni to select from the 
growth area of highest concentration, rather than selection of isolated colonies (Figure 4.1).  
Samples were concurrently passed on MH blood agar and MH medium supplemented with 0.4% 
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agar (motility agar).  Broiler chickens were inoculated with C. jejuni as detailed in the protocols 
of the first broiler chicken study. 
 
4.4 Results  
 
In the first study, in order to confirm the ability of C. jejuni NCTC 11168 to colonize the 
cecum of broiler chickens and to evaluate the efficacy of 2’FL as a treatment strategy, 90 
chickens were divided into six groups (Table 4.3).  Group 1 was the uninoculated, no treatment 
control group, Group 2 was inoculated with C. jejuni and no 2’FL dosage, Group 3 was 
inoculated with C. jejuni and a low 2’FL dosage (1 mg), Group 4 was inoculated with C. jejuni 
and a medium 2’FL dosage (10 mg), Group 5 was an uninoculated, high 2’FL dosage (100 mg) 
group, and Group 6 was inoculated with C. jejuni and a high 2’FL dosage (100 mg).  Birds were 
orally gavaged on 14 d of age and were necropsied on 21 d of age.  Direct plating on Campy-
Cefex agar was performed to determine the level of cecal colonization.   
Enumeration of the cecal samples indicated an absence of C. jejuni in the inoculated 
groups (group 2, group3, group 4, and group 6).  Additionally, C. jejuni was not recovered from 
the uninoculated chickens (group 1 and group 5).  While the higher plating dilutions (10
6
-10
8
) 
did not have bacterial growth, the lower plating dilutions (10
3
-10
5
) had visible bacterial growth 
that was inconsistent with typical C. jejuni colony morphology and was similar for all samples 
regardless of treatment group. 
Therefore, qPCR was conducted to determine the level of colonization below the 
detectable plating threshold of 10
3
 CFU/mL.  Campylobacter spp. primers successfully amplified 
the Campylobacter genomic DNA used for the standard curve.  However, the primer set didn’t 
amplify when using DNA extracted from cecal contents.  Only one treatment replicate was found 
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to have Campylobacter, though at very low levels (10
1
-10
2
 CFU/g) and were amplified in an 
unreliable range (CT>35) outside the standard curve range.  The intention of this study is to have 
definitive C. jejuni colonization of broiler chickens (>10
5
 CFU/g of cecal contents) to evaluate 
novel treatment strategies.  Results indicate the broiler chickens were not successfully colonized 
with C. jejuni NCTC 11168 at day 21 of age.   
To verify the selection of the Campy-Cefex agar, chicken cecum samples were collected 
from the poultry farm and prepared according to the previous instructions (results not shown).  
One set of samples were inoculated with C. jejuni NCTC 11168, while the other group served as 
a negative control.  Plates with the negative control samples (not spiked with C. jejuni) were not 
found to support growth of Campylobacter.  This indicates the bird was not previously colonized 
with Campylobacter.  For the samples inoculated with Campylobacter, the Campy-Cefex agar 
supported the growth of these bacteria.  This isolation indicates the plating method with Campy-
Cefex was successful and confirmed that the broiler chickens were not colonized with C. jejuni 
in Study One.  
Further conversations with collaborators indicated that the C. jejuni NCTC 11168 strain 
used for the broiler chicken inoculum had attenuated motility.  Whether due to the original 
frozen culture or the passage technique, the C. jejuni lacked the flagellar motility necessary for 
colonization of the cecal crypts.  The collaborators shipped an ‘enhanced motility’ strain of C. 
jejuni NCTC 11168 and a passage technique was determined (Figure 4.1).  In addition, the C. 
jejuni must be passed for several days prior to the inoculation, to allow the cells to recover from 
the harsh -80°C conditions.  Along with growth on MH blood agar, the strains were also passed 
concurrently on MH supplemented with 0.4% agar to test for motility.  The motility agar was 
stab inoculated and incubated in microaerobic conditions at 37°C overnight.   
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In the second study, motility assays using MH agar supplemented with 0.4% agar were 
performed to select a highly motile strain (before administration to broiler chickens).  Two C. 
jejuni strains F38011 and NCTC 11168 were chosen for this study, based on their previously 
indicated ability to colonize broiler chickens (Jones et al., 2004, Neal-McKinney et al., 2012).   
To confirm the ability of C. jejuni to colonize the cecum of broiler chickens, 60 chickens 
were divided into four groups, each consisting of 15 birds (Table 4.4).  Group 1 was the 
uninoculated, control group, Group 2 was inoculated with C. jejuni NCTC 11168 on day 10, 
Group 3 was inoculated with C. jejuni NCTC 11168 on day 14, and Group 4 was inoculated with 
C. jejuni F38011 on day 14.  C. jejuni enumeration by direct plating of cecal samples indicated 
successful colonization of the birds with C. jejuni NCTC 11168 and F38011.  The number of 
bacteria recovered per gram of cecum contents varied between birds of the same group (10
3
-10
9
 
CFU/mL).  C. jejuni were not recovered from the uninoculated chickens (group 1), indicating the 
established workflow and sample handling prevented cross-contamination.  The concentration of 
Campylobacter colonized within the cecum varied amongst the broiler chickens, with day 14 
inoculated C. jejuni NCTC 11168 the most robust (Figure 4.2).  C. jejuni were recovered from 
the cecal contents of 13 of 15 birds inoculated with C. jejuni NCTC 11168 on day 10 (group 2).  
C. jejuni were recovered from the cecal contents of 15 of 15 birds inoculated with C. jejuni 
NCTC 11168 on day 14 (group 3). C. jejuni were recovered from the cecal contents of 10 of 15 
birds inoculated with C. jejuni F38011 on day 14 (group 4).  Overall these results indicate an 
ability to colonize the chicken cecum with C. jejuni.  The best strategy for colonization appeared 
to be inoculation with C. jejuni NCTC 11168 on day 14. 
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4.5 Discussion 
 
The objective of this study was to colonize the cecum of broiler chickens with C. jejuni, 
in an effort to establish a model to test novel strategies for the control of C. jejuni colonization.  
C. jejuni isolates selected for this study have previously been shown to colonize chickens (Jones 
et al., 2004, Neal-McKinney et al., 2012).  Of the two isolates inoculated in this study, both were 
able to colonize the cecum of broiler chickens.  Based on direct plating results, C. jejuni NCTC 
11168 was recovered from the cecum in greater numbers than C. jejuni F38011.  In the cecum 
samples collected, concentrations of C. jejuni colonization varied between 10
3
-10
9
 CFU/mL.  
This finding is in agreement with the existing literature, where C. jejuni colonization of the 
mucosal layer of the cecal crypts is between 10
6
-10
9
 CFU/mL (Allen et al., 2008, Beery et al., 
1988, Hermans et al., 2012, Meade et al., 2009).   
Culturing techniques were determined to be critical in the passage of C. jejuni prior to 
administration to the broiler chickens, to maintain colonization potential of the isolates.  It was 
determined that flagellar motility of the selected strains was critical to obtain colonization.  
Therefore, motility assays were developed and employed to ensure the presence of flagella prior 
to inoculation.  Of the two strains inoculated (NCTC 11168 and F38011), both appeared to be 
equally motile therefore both were used for inoculation in the second study.  Care was taken in 
the second study to maintain the motility and chemotaxis of the flagella, which was absent in the 
first study.  It has been reported that the flagellum is critical in colonization of the intestinal 
mucus coating the cecal crypts (Beery et al., 1988).  Important in the flagella motility are the 
presence of two filament genes, flaA (encodes the major flagellin) and flaB (encodes the minor 
flagellin).  While the impact of environmental conditions varies for the activity of these two 
genes, only flaA has been shown to be essential for chicken colonization (Hermans et al., 2011a, 
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Wassenaar et al., 1991, Wassenaar et al., 1993).    Particular C. jejuni mutants that lack flagella 
or have modified chemoreceptors, are unable to colonize the GIT of the chicken (Hermans et al., 
2011a, Kanungpean et al., 2011).  Additionally, deoxycholate, a bile acid, may be added to the 
MH agars during outgrowth from the -80°C to stimulate virulence and assist in colonization of 
the broiler chicken GIT. 
Differential flagellum protein expression between a robust- (A74/C) and a poor-
colonizing (11168) C. jejuni isolate in poultry indicates the importance of the flagellum in 
colonization (Hiett et al., 2008).  The flagella-encoding genes differing between these two 
isolates were located in the hypervariable regions of the C. jejuni genome.  This variability 
evidently extends into the protein level and may influence the survival of the organism in the 
environment and host selection.  In spite of the poor-colonizer stigma, C. jejuni NCTC 11168 
successfully colonized the cecum of 21 d broiler chickens and were enumerated from the cecal 
contents in concentrations up to 10
9
 CFU/mL.  Unfortunately, research is rather limited 
regarding the paralysis of the C. jejuni flagella and subsequent colonization in broiler chickens. 
 
4.6 Conclusion 
 
In summary, we were able to successfully colonize broiler chickens with C. jejuni.  
Establishment of the sound study parameters allows us to explore a variety of novel strategies for 
the control of C. jejuni colonization.  In the future, broiler chickens should be inoculated on day 
14 with a highly motile C. jejuni NCTC 11168.  Additionally, handling techniques of the C. 
jejuni isolates prior to administration are critical to the colonization ability of the strains.  Prior to 
inoculation, passage on motility assays is highly encouraged, to verify the presence of the 
flagella which is critical for colonization of the mucosal layer overlaying the cecal crypts.     
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4.8 Tables and Figures 
 
Table 4.1 Proposed timeline for animal facility preparation.  
 
Task 
6 
weeks 
Prior 
5 
weeks 
prior 
3 
weeks 
prior 
2 
weeks 
prior 
1 
week 
prior 
Minus 
2 days 
Minus 
1 day 
Day 
0 
Day 
22 
Design of 
Experiment 
x                 
Verify Facility 
Availability 
x                 
Send DAR Bird 
Order 
  x               
Contact Poultry 
Farm for 
Wingband and 
Feed Order 
    x             
Notify Laboratory 
Group of Study 
Dates 
    x             
Prepare Study 
Materials 
    x x x         
Coordinate Feed 
Delivery 
        x         
Set-up Batteries 
and ERML 
Rooms 
          x       
Add Feed and 
Water to batteries 
          x x     
Chick Arrival               x   
Study Clean-up                 x 
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Table 4.2 Composition of standard diet 4 without bacitracin on percentage basis. Prepared by the 
University of Illinois Urbana-Champaign Poultry Farm. CP, crude protein. 
 
INGREDIENT % 
Fine Ground Corn (1/8" screen) 52.85 
Dehulled SBM (47% CP) 37.50 
Pork Meal (50% CP) 2.00 
Dicalcium Phosphate 1.50 
Limestone 1.10 
Salt 0.40 
Poultry Trace-Mineral Premix 0.15 
DL-Methionine 0.20 
Choline Chloride (60%) 0.10 
Poultry Vitamin Premix 0.20 
Soybean Oil 4.00 
Total 100.00 
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Table 4.3 Experimental design of first broiler chicken study.  To assess the effect of 2’FL-
inoculation on C. jejuni colonization of broiler chickens. 
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Table 4.4 Experimental design of second broiler chicken study. Assess the effect of timing on C. 
jejuni colonization of broiler chickens. 
 
 
1 2 3 4 
Challenge Day d 14 d 10 d 14 d 14 
C. jejuni 
inoculation 
PBS only 
C. jejuni NCTC 
11168 
C. jejuni NCTC 
11168 
 C. jejuni NCTC 
F38011 
 
n = 15 n = 15 n = 15 n = 15 
DAY 21                 
Necropsy   SAMPLES= 1) Cecum 
  
  
 
      2) Freeze cecum sample      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
115 
 
Figure 4.1 Experimental Campylobacter handling procedures. Campylobacter passage on 
Mueller-Hinton (MH) blood agar and motility test on MH supplemented with 0.4% agar.  A 
dense growth area is selected, over the traditional individual colony isolation.  
 
 
 
 
 
 
 
 
 
 
116 
 
Figure 4.2 C. jejuni colonization of cecum. Broiler chickens were colonized with C. jejuni 
NCTC 11168.  Cecum samples were collected from broiler chickens on d 21.  The materials and 
methods describe the enumeration of CFU per gram of cecal content.  N indicates the number of 
chickens of each group of 15 that were colonized with C. jejuni (limit of detection, 10
3
 CFU/g of 
cecal contents).  The bar indicates the median CFU for each group, which was determined using 
all birds within the group.  The absence of a bar indicates the number of C. jejuni cells was 
below the limit of detection.  
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CHAPTER 5 SUMMARY AND FUTURE DIRECTION 
 
 
 Strategies to reduce Campylobacter jejuni colonization of broiler chickens at the poultry 
farm remain limited.  The literature indicates current intervention techniques incompletely 
prevent colonization of C. jejuni, though a minor reduction in colonized broiler chickens may 
significantly reduce the incidence of campylobacteriosis.  A novel strategy builds on the innate 
probiotic mechanisms of lactobacilli.  Herein, we described the construction of antigen-
presenting vectors for lactobacilli vaccine delivery to the gastrointestinal tract of broiler 
chickens.  The antigen-presenting vectors either anchored or secreted the C. jejuni cell surface 
adhesion, FlpA DII (antigen), to the exterior cell surface of recombinant Lactobacillus spp.  An 
alternate strategy explored the non-covalent attachment of C. jejuni FlpA DII to the surface of 
Lactobacillus spp. through three cell wall binding domains, L. gasseri ATCC 33323 LysM 
protein, L. gasseri ATCC 33323 Lysozyme M1 – bacterial SH3 domain, and L. lactis susbp. 
cremoris MG1362 AcmA protein.  In addition, establishment of study procedures to colonize 
broiler chickens with C. jejuni provided a foundation for exploring oral administration of in vivo 
treatment strategies. 
 Throughout the course of this project, we encountered several learning points to consider 
for future work. 
First, verification of protein expression from the recombinant Lactobacillus spp. proved 
more challenging than anticipated.  Both sonication and boiling of the supernatant and cell pellet 
were employed to evaluate protein expression.  However, these procedures were inadequate to 
detect the C. jejuni FlpA DII expressed by recombinant Lactobacillus spp.  Verifying the protein 
expression of the recombinant Lactobacillus spp. is imperative prior to oral administration of 
118 
 
broiler chickens.  Treatment strategies will only be explored upon approval of full diagnostic 
analysis of the recombinant Lactobacillus spp.   
 Second, we will explore a non-genetically modified Lactobacillus strain that displays C. 
jejuni FlpA DII.  Cell wall binding domains are effective in non-covalent attachment of 
heterologous proteins to the surface of lactobacilli.  However, additional research remains to be 
conducted on the in vivo stimulation of the immune response and stability of the protein through 
the gastrointestinal tract.   
 Third, animal trials resulted in successful colonization of the broiler chicken cecum with 
C. jejuni.  The flagellar motility of the C. jejuni strains was found to be integral to broiler 
chicken colonization.  While C. jejuni NCTC 11168 is considered a poor colonizer, in these 
studies the strain achieved colonization of the cecum at a higher concentration than that of C. 
jejuni F38011.  As the laboratory handles additional C. jejuni strains for experimental protocols 
and preparation for in vivo colonization, care will be taken to maintain flagellar motility.   
From the animal studies and laboratory experiments, we gained distinct insights for 
future work to focus upon.  This includes verifying the recombinant protein expression in the 
supernatant and the cell wall of lactobacilli, exploring a non-genetically modified Lactobacillus 
spp. for cell wall binding of a heterologous protein, and handling procedures of C. jejuni will be 
followed to ensure motility of strains and subsequent colonization.  The work conducted in this 
thesis provides a foundation for further research on the reduction of C. jejuni colonization of 
broiler chickens.  
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APPENDIX A. ELECTROCOMPETENT ESCHERICHIA COLI 
 
1. Inoculate 200mL LB with E. coli MC1061 (from frozen stock).  Use 1-Liter flask, 
incubate at 37 C, and shake at 250 rpm. 
 
2. Monitor OD.  When it reaches 0.5 to 0.6, transfer cells to a 250mL centrifuge bottle (pre-
chilled) and centrifuge the cells at 3,200 × g, 4° C for 10 minutes. 
 
3. Wash the cells 3X with pre-chilled sterile water 
 
4. Wash with sterile 10% glycerol (prechilled) 
 
5. Resuspend cells to a final volume of 1-1.5mL in 10% glycerol 
 
6. Dispense cells to Eppendorf tubes on ice (85uL per tube is good) 
 
7. Store tubes at –80°C until use. 
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APPENDIX B. ESCHERICHIA COLI TRANSFORMATION 
 
1. One tube per transformation, chill tube on ice. 
 40mL electrocompetent cells per tube 
 2mL lig. Mixture or up to 16mL if clean DNA 
 
2. Transfer cells/DNA to a 0.2 micron cuvette (pre-chilled) 
 
3. Zap at 2.5 V, 200 ohms, and 25 uFD (capacitance).  Time constant should be near 1.0 
 
4. Add 960mL of pre-warmed (37C) LB to tube and transfer contents to small culture tube 
 
5. Incubate at 37C for 1 hour with shaking 
 
6. Plate cells on appropriate plates (10mL and 100mL) 
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APPENDIX C. LACTOBACILLUS TRANSFORMATION 
 
Electroporation Buffer: 1M Sucrose  171.1g   or  342.2g 
      (3.5X SMEB)  3.5mM MgCl2 0.356g 0.712g 
    ddH2O up to  500mL 1L 
 
 pH should be around 7.0 
 Filter sterilize through 0.2μm membrane 
 
1. Inoculate 100mL MRS with 1mL of an overnight culture and incubate at 37C until it 
reaches an OD600 = 0.5 – 0.8. 
a. Pre-warm the MRS for faster growth 
b. Take 3.5-5.5 hours to get to 0.5 
c. All liquid cultures can be done outside the anaerobic chamber; however, do not 
use a shaker 
 
2. Centrifuge culture at 3,200 × g for 10min at 4°C and wash with cold 3.5X SMEB.  
Centrifuge in 2, 50 ml conical tubes  
a. Resuspend each pellet in 20 ml 3.5X SMEB (40 ml total) 
b. Can combine into one tube if desired but use 40 ml per wash 
 
3. Repeat step 2 at least twice for three total washes. 
 
4. Resuspend cells in 1.0mL 3.5X SMEB (concentrate 100 fold). 
a. Mix well using a pipettor 
 
5. Transfer 0.2mL cells to a microfuge tube and add DNA; mix and transfer to a cold 0.2cm 
cuvette. 
 
6. Electroporate at 2.45kV, 25μFD, 200Ω. 
a. We now use an eppendorf electoporator that has only a voltage setting (we use 2.5 
kV; typical time constant is ~3.3) 
 
7. Transfer cells (gently) to 3.0mL MRS and incubate at 37C. 
a. ~16 hours is sufficient 
b. Does not need to be in anaerobic shaker but no shaking 
c. We use small culture tubes but you could use falcon tubes 
 
8. Dilute cells accordingly and plate on MRS plus appropriate antibiotic. 
a. L. gasseri ATCC 33323 – 5.0 mg/ml erythromycin 
b. Make sure you plate a negative control 
c. I usually use add 40ml and 200ml on two plates each 
 
9. Incubate 2-3 days in anaerobic chamber at 37C 
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APPENDIX D. LACTOBACILLUS PLASMID ISOLATION PROTOCOLS 
 
RAPID LACTOBACILLUS MINI-PREP PLASMID ISOLATION PROCEDURE 
 
(DANIEL J. O'SULLIVAN AND TODD R. KLAENHAMMER, 1993, Rapid Mini-Prep 
Isolation of High-Quality Plasmid DNA from Lactococcus and Lactobacillus spp. Appl. Environ. 
Microbiol. 59:27302733) 
 
Procedure is as follows: 
 
A. Make 5 or 10 ml overnight broth culture 
 
B. Pellet entire amount in 15 ml plastic conical tube: 3,200 × g/10 min at 4oC 
 
C. Wash cell pellet with 10 ml dd H20, re-centrifuge (same conditions). 
 
D. Resuspend pellet with 200 ul 25% sucrose containing 30 mg/ml Lysozyme (10 mg/ml, 
stored at 4°C) and Transfer cell suspension to 1.5 mL eppendorf tube, incubate 15 min at 
37
 o
C  
 
E. Add 400 ul of alkaline SDS solution, mix immediately and incubate 7 min at RT  
 
F. Add 300 ul ice cold 3M sodium acetate (PH 4.8), mix well and spin max speed 15 min at 
4
 o
C 
 
G. Transfer supernatant to new 1.5 mL eppendorf tube and 650 ul of isopropanol (RT), mix 
well and spin max speed 15 min at 4
 o
C 
 
H. Remove all liquid and resuspend pellet in 320 ul dd H20. 
 
I. Add 200 ul of 7.5M ammonium acetate containing 0.5 mg/ml ethidium bromide 
 
J. Add 350 ul chloroform and mix well and spin max speed 5 min at RT 
 
K. Transfer upper phase to new eppi and add 1 ml ethanol (-20°C) mix well and spin max 
speed 15 min at 4
 o
C 
 
L. Rinse pellet with 500 ul 70% ETOH; recentrifuge for 1 min (conditions of Step J); dry 
pellet for 30 minutes (modified – 2-3h in Biosafety Cabinet with fan on). 
 
M. Add 40 ul Nanopure, RNAse-free H20 containing RNase (0.1 mg/ml)  
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APPENDIX D. CONTINUED 
 
LACTOBACILLUS MINI-PREP PLASMID ISOLATION PROCEDURE 
 
I.    Procedure is as follows:  
A.  Inoculate 10 ml MRS broth with 2 ml of overnight culture.  Incubate at 37°C for 2 hours.    
  
B.  Pellet entire amount in 15 ml plastic conical tube: 3,200 × g/10 min at Room Temperature. 
 
C.  Wash cell pellet with 5 mls dd H20, re-centrifuge (same conditions). 
 
D.  Resuspend pellet with 1.0 ml cell suspension buffer (Soln A, stored at 4°C) containing 
Lysozyme (10 mg/ml, stored at 4°C) and hold on ice 1.0 hour.  Resuspend by pipetting on ice.  
Check to ensure that water bath is at 65°C (for step H). 
 
E.  Transfer cell suspension to 2.0 mL eppendorf tube with screw cap and pellet in microfuge for 
1.0 minute at 8,327 × g.  Pour off supernatent. 
 
F. Add 500 ul pH adjusted Lysis solution (Soln B) to cell pellet.  Add NaOH to Lysis solution 
just before use.  Test pH with paper. 
 
G.  Disrupt pellet by aspiration with pipetman and vortex vigorously for 20-30 seconds. 
 
H.  Heat eppendorf tubes at 65°C for 30 min.  Cool 10 min. at RT (room temp). 
 
I.  Add 250 ul of High Salt Solution; mix well by tapping (if the target plasmid is larger than 10 
KB) or invert vortexing (if smaller than 10 KB).   
 
J.  Add 400 ul of Tris Saturated Phenol (bottom layer); invert to mix. 
 
K.  Add 400 ul of Chloroform; invert to mix. 
 
L.  Centrifuge at 6,118 × g in microfuge for 5 minutes. 
 
M.  Transfer aqueous layer (on top) to a new 2.0 mL eppendorf tube with screw cap (upper layer; 
approx. 750 ul); add 750 ul (Chloroform: isoamyl alcohol (24:1)) and mix. 
 
N.  Centrifuge at 6,118 × g in microfuge for 5 minutes. 
 
O.  Transfer aqueous layer to a new 1.5 mL eppendorf tube with flip cap and add 750-800 ul 
100% isopropanol to fill the tube, mix well by inversion. 
 
P.  Chill isopropanol preps at -20°C for at least 30 minutes.  Turn on microfuge to 4°C. 
 
Q.  Spin in 4°C microfuge at 6,118 × g for 15 min. 
 
124 
 
APPENDIX D. CONTINUED 
 
R.  Pour off isopropanol and rinse pellet with 500 ul 70% ETOH; recentrifuge for 2 min (cond. 
of Step Q); dry pellet for 15 minutes (modified – 2-3h in Biosafety Cabinet with fan on). 
 
S.  Add 50 ul Nanopure, RNAse-free H20 containing RNase (20 ug/ml) (2 ul 500 ug/ml). Leave 
in refrigerator overnight, store in -20°C. 
 
Notes: 
 For Lactococcal plasmid isolation, phase-shift (Step A and B) may not be required; just use 
5-10 ml of overnight culture.  
 In most cases, adjustment of pH of lysis solution to 12.4 is essential.  If you don't observe 
good lysis, check pH. 
 Disruption of cell pellet by pipetman at step G is boring but essential.  Do it until you 
observe clearance of soln. 
 Heating at 65°C and slow cooling to room temperature is helpful to remove chromosomal 
DNA; however, plasmid larger than 25 KB may be removed together. 
 For restriction digestion, washing the DNA pellet with 70% ethanol at room temp is critical. 
 For very low copy number DNA, or larger plasmid DNA, TE-saturated phenol (pH 7.0-8.0) 
is helpful. 
 
II. Prepare the following solutions: 
 A.  Cell Suspension Buffer  (100 ml). Filter sterilize and store at 4 degrees. 
      50 mM Tris-Cl  5 ml 1.0 M Tris-Cl  (pH 8.0) 
     0.2 ml 0.5 M EDTA  (pH 8.0) 
      8% Sucrose  8.0 g 
    
B.  Lysis Solution (100 ml).  
      50 mM Tris-Cl  5 ml 1.0 M Tris-Cl (pH 8.0) 
      5 mM EDTA  1 ml 0.5M EDTA (pH 8.0) 
      3% SDS   30 ml 10% SDS Soln. (Made in dd H2O) 
 
Add approximately 35 ul of 3.0 N NaOH/ml lysis solution until the pH is 12.4, just 
before use at Step F.  Measure 10 ml water into tube, add 1.2g NaOH. Filter Sterilize 
and store at room temperature. 
 
C.  High Salt Solution (100 ml).  
      3.0 M Potassium Acetate 29.4 g 
      1.8 M Formic Acid 5.0 ml (90%) 
 
     Filter Sterilize if there is a brown precipitate and store at  room temperature. 
 
 D.  STE 
      0.1 M NaCl  2 ml 5.0 M Stock Solution 
      10 mM Tris-Cl  1 ml 1.0 M Tris-Cl (pH 8.0) 
      1 mM EDTA  0.2 ml 0.5 M EDTA (pH 8.0) 
125 
 
APPENDIX E. CAMPY-CEFEX AGAR DIRECTIONS 
 
Base (per 750 mL) 
43 g Brucella Agar – BD (Fischer # B11086) 
Supplement: Add to 750 mL after autoclaving and tempering to 55°C. 
1. 25 mL citrated blood 
2. 3 mL of sterile-filtered FS/SP/SM solution 
 
To make solution, to 20 mL water add: 
2.5g Sodium Pyruvate 
2.5g Ferrous Sulfate 
1.0g Sodium Metabisulfite 
Note: Sterile filter solution and protect from light! Make fresh each time!  Should have a 
red-brown appearance  
 
3. 2mL Cefoperazone  stock: Dissolve 125 mg in 10 mL of 50% Ethanol 
4. 2mL Cyclohexamide  stock: Dissolve 750 mg in 10 mL of 50% Ethanol 
 
*Note: Add stir bar and leave when autoclaving.  Add each ingredient to the autoclaved media 
separately. Mixing any of the 4 supplement solutions together will cause precipitation. 
 
Ingredients Concentration (per 750 mL) 
BD Brucella Agar 43 g 
Bovine Citrated Blood 25 mL 
Sodium Pyruvate 375 mg 
Ferrous Sulfate 375 mg 
Sodium Metabisulfite 15 mg 
Cefoperazone 25 mg 
Cyclohexamide 150 mg 
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APPENDIX F. TOTAL FECAL DNA EXTRACTION 
 
Total DNA Extraction from Fecal Samples and 3
rd
 Stage in vitro Samples 
(Repeated Bead Beating Plus Column (RBB+C) Method) 
Last modified: 6/25/07 by Ingmar 
Estimated time from start to finish for two batches of 8 extractions: ~7 hours (depending on 
experience)  
 
Reference:   
Yu, Z. and M. Morrison. 2004. Improved extraction of PCR-quality community DNA from 
digesta and fecal samples. Biotechniques 36:808-812. 
 
Reagents (Not Included in Kit) 
 
 Tris-HCl (500 mM, pH 8.0): Place 30.28g of Tris in a 500 mL volumetric flask; add 
~300 mL milliQ water. Then bring to pH 8.0 by adding concentrated (1M or higher) HCl, then 
add milliQ water to volume. 
 EDTA (500 mM, pH 8.0): Place 93.05g of EDTA Disodium Salt Dihydrate in a 500 mL 
volumetric flask; add ~300 mL milliQ water – heating helps EDTA dissolve; adjust pH close to 
8.0 (EDTA only completely dissolves at ~pH 8.0 – when all is dissolved, adjust pH to 8.0, then 
bring to volume). Autoclave for 15 minutes (if immediately making a solution with this stock, 
you can use the fresh EDTA solution)   
 Lysis Solution: Place 7.3 g of NaCl and 10 g SDS in an autoclavable bottle; add 25 mL 
of 500mM Tris-HCl; add 25 mL of 500mM EDTA; add 200mL milliQ water. Stir on a 
hotplate/stirrer (medium temperature) to dissolve the SDS (this takes a while) – do NOT shake 
agressively, this solution foams excessively. Take out the stir bar, then autoclave. 
NOTE: This solution separates easily – after autoclaving, a STERILE stir bar can be added 
back. Stir on a medium temperature hotplate before use (solution should be clear) 
 10M NH4-Acetate: place 38.54 g Ammonium acetate in a 50 mL volumetric flask; bring 
up to volume. Mild heating will ease dissolving.  
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 TE Buffer: pipet 10mL Tris-HCl (500 mM) and 1mL of 500mM EDTA into a 500mL 
volumetric flask. Bring to volume, autoclave for 15 minutes. 
 70% Ethanol: bring 70mL of 100% ethanol to 100 mL volume 
 100% Ethanol 
 Isopropanol 
 DNase-free RNase: get at the life sciences store-room (Roche catalog #11119915001) in 
1 mL tube – good for ~25 extractions. If you know you need large quantities (many extractions) 
you may want to order directly from Roche – the store room only has a few vials in stock. 
 
Procedure 
 
Sample collection for in vitro samples only: Place in the -80C as soon as possible. 
 
Day 1:  
 
Part I:  
Cell Lysis: 
Suggestion for fecal samples: do a 105 dry matter on the sample you actually extract.  
Turn on the water baths to 37 & 70C, and let the centrifuge cool to 4C 
To ensure all fluid is incubated properly, you need to spin your tubes in the micro- centrifuge for 
2-3 seconds – this is referred to as “quick-spin” 
- Weigh up 0.4 g of sterile zirconia/glass beads in 2-mL screw-cap tubes using the 
porcelain scoop 
o 0.4g Disruption Beads (RPI 9830) 
- Transfer 0.25 g (or 400ul for in vitro samples) of sample into a fresh 2-mL screw-cap 
tube (acceptable weight range: 0.20 – 0.32 g) – try to keep the rim clean and to not 
have the sample stick to side of the tube. 
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- Add 1 mL of lysis solution to the tube and vortex at full speed until beads and sample 
are reasonably mixed (make sure no sample is sticking to the wall of the tube) 
- Homogenize for 3 min at maximum speed with a vortex (tube adapter) 
- Incubate at 70oC for 15 min with gentle shaking (inverting) by hand every 5 min 
- Centrifuge at 4oC for 5 min at 16,000 X g 
- Pipet the supernatant into a fresh 2-mL Eppendorf tube  
- Add 300 L of fresh lysis buffer to the screw-cap tube 
- Vortex until mixed – make SURE to break up the pellet at the bottom of the tube 
- Homogenize for 3 min at maximum speed with a vortex (tube adapter) 
- Incubate at 70oC for 15 min with gentle shaking (inverting) by hand every 5 min 
- Centrifuge at 4oC for 5 min at 16,000 X g. 
- Combine the supernatant with the supernatant collected previously 
 
Precipitation of Nucleic Acids 
- Add 260 L of 10 M ammonium acetate to each tube, vortex to mix. 
- Incubate on ice for 5 min 
- Centrifuge at 4oC for 10 min at 16,000 X g 
- Transfer (split) supernatant into two 1.5-mL Eppendorf tubes (use fixed volume, 
600 L will get you most, if not all supernatant) 
- Add an equal volume of isopropanol to each eppendorf and mix well 
- Incubate on ice for 30 min 
- Centrifuge at 4oC for 15 min at 16,000 X g 
- Carefully pipet off the supernatant, make sure to leave pellet intact! 
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- Wash the nucleic acids pellet by adding 0.5 mL with 70% ethanol, centrifuge at 4oC 
for 1 minute at 16,000 X g (to make sure the pellet is intact), then carefully pipet off 
ethanol – do not damage the pellet! 
NOTE: after this step, set the centrifuge to warm up to room temp for the next 
centrifugation steps 
- Dry the pellet in a BSC for 30 mins 
- Dissolve the nucleic acid pellet in 100 L of TE (Tris-EDTA) buffer, this takes some 
effort – pellet is re-hydrated overnight at 4C. 
Day 2: 
- Pool the two aliquots of dissolved pellet into one tube 
 
Removal of RNA 
- Add 40 L of DNase-free RNase (final [0.1 g/L]). Vortex and quick-spin. 
- Incubate at 37oC for 15 min 
Part II: 
Removal of Protein and Purification (Partial Qiagen Stool Mini Kit – Centrifugation at Room 
Temp) 
- Add 15 L of proteinase K, vortex and quick-spin 
- Add 200 L of Buffer AL, vortex and quick-spin 
- Incubate at 70oC for 10 min 
- Add 200 L of ethanol, vortex and quick-spin, and pipet all liquid to a QIAmp 
column (don’t wet the rim) and centrifuge at 16,000 X g for 1 min at room temp 
- Insert columns into a new 2 mL collection tube 
- Add 500 L of Buffer AW1 and centrifuge at 16,000 X g for 1 min, insert columns 
into new 2 mL collection tube 
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- Add 500 L of Buffer AW2 and centrifuge at 16,000 X g for 1 min, insert columns 
into new 2 mL collection tube 
- Dry the column by centrifugation at RT for 1 min (16,000 X g), insert columns into 
an appropriately labeled 1.5 mL eppendorf tube 
- Add 200 L of Buffer AE and incubate at RT for 4 min 
- Centrifuge at RT for 1 min to elute DNA and read a 2 L sample on the Nano-drop 
spec 
- Freeze samples at -20oC for storage or until further use 
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APPENDIX G. RECOMBINANT LACTOBACILLI DOSAGE OF BROILER  
 
CHICKENS 
 
G.1 Materials and Methods 
 
The primary objective of this study was to evaluate the immune response of 
administering recombinant lactobacilli strains to Ross 308 broiler chickens.  The recombinant 
lactobacilli strains expressed C. jejuni FlpA either on the surface of the bacterial cell or into the 
supernatant.  The study consisted of seven randomly assigned groups, consisting of one control 
group and six recombinant Lactobacillus groups (Table G.1).  At 6 and 16 days of age, broiler 
chickens were orally administered with the treatment dosage (Table G.2).  Each treatment group 
was assigned three cages of birds, which each held five birds, for a total of fifteen birds within 
each treatment group.  Necropsy was spread across three days, to evaluate the host immune 
response.  Necropsy occurred on day 16, day 18, and day 20, with one cage selected from each 
treatment group per necropsy day. 
 
Broiler Chickens  
Day-old chickens were randomly divided into study groups and placed into cohabitated 
stainless steel batteries (Table G.1).  Broiler chickens inoculated with C. jejuni were housed 
separately from control broilers, with an established workflow to reduce risk of cross-
contamination.  Water and standard diet without bacitracin were provided ad libitum.  Fecal 
material was collected in a removable metal tray below the wire mesh floor of the cage.  The 
following studies were conducted at the University of Illinois with experiments and procedures 
approved by the Institutional Animal Care and Use Committee (IACUC; protocol no. 13059).   
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Lactobacillus Dosage 
Methods in Chapter 3 detail the construction of the recombinant Lactobacillus strains 
used in this study.  As previously described in Chapter 3, broiler chickens were orally gavaged 
with 0.5 mL of suspended Lactobacillus strains (~10
7
 CFU/mL) on days 6 and 16 of age.  A 
frozen stock was passed four times in MRS + ERM (2.5 µg/mL) at 37°C under anaerobic 
conditions.  The samples were serially diluted in PBS to the proper optical density at 600 nm 
wavelength (OD600 nm, Spec 21, Bausch and Lomb) and serial dilutions were performed to verify 
the concentration.  The inoculated samples were plated on MRS + ERM (2.5 µg/mL) and 
enumerated after 48 h incubation.  Control birds received PBS without Lactobacillus, on the 
same dosage timeline.  Birds necropsied on d 16 did not receive the Lactobacillus dosage on d 
16.  
 
Enumeration of Cecal Lactobacillus Populations 
As previously described under “Enumeration of Cecal Campylobacter Populations,” the 
cecal dilutions were spread plated on MRS + ERM (2.5 µg/mL) agar plates (Chapter 3).  Plates 
were incubated anaerobically at 37°C for 48 h and plates were enumerated (round, with white- or 
cream-colored colonies) and recorded.  All bacterial enumerations were performed in duplicate. 
 
Serum Collection 
Shortly after euthanasia and incision of the chest cavity, blood samples were drawn from 
the heart of broiler chickens to ensure sufficient sample collection.  Attached to a BD 
Vacutainer
®
 Needle Holder, 21-gauge BD Vacutainer
®
 blood collection needles were placed  
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directly into the heart and blood collected in a 4 mL BD Vacutainer
® 
Rapid Serum Tube (VWR, 
Pennsylvania, USA).  Blood samples were allowed to remain at room temperature and to clot in 
the upright position for at least 30 min but no longer than 1 h, before being placed onto ice.  
Samples were then centrifuged at 4°C for 10 min at 1,000-2,000 × g.  Serum aliquots of 0.5 mL 
were transferred into plastic screw-cap vials and stored at -20°C.     
 
Protein Verification 
Lactobacillus cultures were grown in MRS broth for sample preparation divided into 
broth culture supernatant, sonicated supernatant, and resuspended pellet.  For the sonicated 
supernatant, the initial bacterial pellets were resuspended in PBS and sonicated for 10 min.  The 
resuspended pellet in PBS was recovered from the post-sonicated sample, due to difficulty in 
centrifuging the sample.  All three samples were mixed with 1× laemelli buffer and boiled 10 
min (>95°C) before running the samples on gels for blotting.  The protein sequence of C. jejuni 
flpA Domain II is predicted to have a size of 11 kD.   
 
G.2 Results and Discussion 
 
Contaminating growth was evident on all cecal content dilutions, with Lactobacillus 
colonies difficult to visualize on higher dilutions.  Lactobacillus isolates were not further 
analyzed to verify the identity of the strains.  Future studies must verify the ability of the direct-
plating method to select for the organism of interest in the presence of background growth. 
Upon further analysis of the inoculated recombinant Lactobacillus strains using Western 
Blot analysis, a protein band of the predicted 11 kD was not present on the gel.  In addition, a  
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plasmid producing C. jejuni flpA could not be verified.  Based on the lack of protein expression 
by the Lactobacillus strains, it was determined that the supposed recombinant strains did not 
actually produce the C. jejuni FlpA DII as desired.  As the strains did not express the protein of 
interest, further work did not evaluate the immune response of the broiler chicken.  Future 
analysis of the recombinant Lactobacillus strains must take into account the stability of the 
plasmid under laboratory conditions as well as the gastrointestinal tract.  The vector structure 
must be evaluated to verify the functionality of the translational components, including the 
promoter and ribosome binding site.   
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Table G.1 Orally gavaged Lactobacillus strain groups. Treatment groups orally gavaged to 
broiler chickens on d 6 and d 16.   
 
Treatment Strain Lactobacillus strain 
Protein 
Expression 
Plasmid 
1 n/a n/a 
Negative 
Control 
n/a 
2 MJM274 L. crispatus CC1-1 Control pMJM8 
3 MJM270 L. crispatus CC1-1 
Secreted + 
Anchored 
pMJM13 
4 MJM271 L. crispatus CC1-1 Secreted pMJM14 
5 MJM275 L. gallinarum ATCC 33199 Control pMJM8 
6 MJM272 L. gallinarum ATCC 33199 
Secreted + 
Anchored 
pMJM13 
7 MJM273 L. gallinarum ATCC 33199 Secreted pMJM14 
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Table G.2 Assess the probiotic and vaccine effect of recombinant Lactobacillus dosage on C. 
jejuni colonization of broiler chickens. 
 
 
1 2 3 4 5 6 6 
DAY 6 & 16 PBS 
only 
MJM 
274 
MJM 
270 
MJM 
271 
MJM 
275 
MJM 
272 
MJM 
273 Lactobacillus dosage 
 
n = 15 n = 15 n = 15 n = 15 n = 15 n = 15 n = 15 
DAY 16, 18 & 20 
                        
 
  
  
 
SAMPLES= 1) Cecum 3) Serum 
  
  
Necropsy           2) Freeze cecum sample        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
